[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"graft-versus-host-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:graft-versus-host-disease":29},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,28,0,25,[9,44,74,103,125,150,175,201,224,250,279,304,328,360,383,411,429,460,482,509,529,550,576,604,637],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100592645","phase-1-emapalumab-with-post-transplant-cyclophosphamide-tacrolimus-and-mycophenolate-mofetil-for-the-prevention-of-graft-versus-host-disease-after-donor-reduced-intensity-hematopoietic-cell-transplant-100592645",false,"NCT06996119","Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versus-Host Disease After Donor Reduced-Intensity Hematopoietic Cell Transplant","Pilot Study of Emapalumab With Post-Transplant Cyclophosphamide as Graft-Versus-Host Disease Prophylaxis for Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation","Inclusion Criteria:\n\n* Documented informed consent of the participant and\u002For legally authorized representative\n\n  * Assent, when appropriate, will be obtained per institutional guidelines\n* Age: ≥ 18 years and ≤ 75 years\n\n  * Note: Patients \\> 70 years of age must have Karnofsky performance status ≥ 80% and HCT-comorbidity index (CI) ≤ 2\n* Karnofsky performance status ≥ 70%\n* Patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) in complete remission with bone marrow (BM) blast of \\\u003C 5%. AML must be negative for minimal residual disease (MRD-)\n* Planned to undergo reduced-intensity conditioning (RIC) with either fludarabine\u002Fmelphalan (Flu\u002FMel) or busulfan\u002Ffludarabine (Bu\u002FFlu) regimens prior to an allogeneic HCT using a mobilized peripheral blood stem cell (PBMC) graft from an 8\u002F8 match related\u002Funrelated donor (A, B, C, DR by high resolution typing)\n* Total bilirubin ≤ 1.5 x upper limit of normal (ULN) (unless has Gilbert's disease)\n* Aspartate aminotransferase (AST) ≤ 3.0 x ULN\n* Alanine aminotransferase (ALT) ≤ 3.0 x ULN\n* Creatinine clearance of ≥ 60 mL\u002Fmin per 24-hour urine test or the Cockcroft-Gault formula\n* Left ventricular ejection fraction (LVEF) ≥ 50%\n\n  * Note: To be performed within 30 days prior to day 1 of protocol therapy\n* Bazett's correction formula (QTcB) ≤ 480 ms\n* If able to perform pulmonary function tests: forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC) and diffusion capacity of the lung for carbon monoxide (DLCO) (diffusion capacity) ≥ 50% of predicted (corrected for hemoglobin).\n* If unable to perform pulmonary function tests: Oxygen (O2) saturation \\> 92% on room air\n* Seronegative for HIV antigen (Ag)\u002Fantibody (Ab) combo, hepatitis C virus (HCV), active hepatitis B virus (HBV) (surface antigen negative) OR\n\n  * If seropositive for HIV, HCV or HBV, nucleic acid quantitation must be performed. Viral load must be undetectable\n* Meets other institutional and federal requirements for infectious disease titer requirements\n\n  * Note Infectious disease testing to be performed within 28 days prior to day 1 of protocol therapy\n* QuantiFERON-TB Gold+\n\n  * Administer tuberculosis prophylaxis to patients at risk for tuberculosis, or known to have a positive purified protein derivative (PPD) test result, or positive interferon gamma (IFNγ) release assay\n* Women of childbearing potential (WOCBP): negative urine or serum pregnancy test\n\n  * If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required\n* Agreement by females and males of childbearing potential to use an effective method of birth control or abstain from heterosexual activity for the course of the study through at least 180 days post-HCT\n\n  * Childbearing potential defined as not being surgically sterilized (men and women) or have not been free from menses for \\> 1 year (women only)\n\nExclusion Criteria:\n\n* Prior allogeneic HCT\n* Other cancer therapies (chemotherapy, radiation, biologics) are not allowed within two weeks of starting HCT conditioning; however targeted agents for underlying hematologic malignancies may be continued up to one day before conditioning, including, but not limited to:\n\n  * FLT3 inhibitors\n  * IDH1\u002F2 inhibitors\n  * Menin inhibitors\n  * ABL-BCR inhibitors\n  * BCL-2 inhibitors\n  * Hydroxyurea\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to study agent\n* Psychological issues, no appropriate caregivers identified, or non-compliant to medication\n* Clinically significant uncontrolled illness\n* Active uncontrolled infections (bacterial, viral, fungal). Infections are considered controlled if appropriate therapy has been initiated and, at the time of screening, no signs of infection are present\n* Other active malignancy\n* Females only: Pregnant or breastfeeding\n* Any other condition that would, in the investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns with clinical study procedures\n* Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility\u002Flogistics)","ALL","18 Years","75 Years",{"count":21,"type":22},15,"ESTIMATED","INTERVENTIONAL",[25],"PHASE1","This phase I trial tests the safety, side effects and effectiveness of emapalumab with post-transplant cyclophosphamide, tacrolimus, and mycophenolate mofetil in preventing graft-versus-host disease (GVHD) in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) after reduced-intensity donor (allogeneic) hematopoietic cell transplant (HCT). Giving chemotherapy, such as fludarabine, melphalan, or busulfan, before a donor \\[peripheral blood stem cell\\] transplant helps kill cancer cells in the body and helps make room in the patient's bone marrow for new blood-forming cells (stem cells) to grow. When healthy stem cells for a donor are infused into a patient (allogeneic HCT), they may help the patient's bone marrow make more healthy cells and platelets. Allogeneic HCT is an established treatment, however, GVHD continues to be a major problem of allogeneic HCT that can complicate therapy. GVHD is a disease caused when cells from a donated stem cell graft attack the normal tissue of the transplant patient. Emapalumab binds to an immune system protein called interferon gamma. This may help lower the body's immune response and reduce inflammation. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid and may kill cancer cells. It may also lower the body's immune response. Tacrolimus is a drug used to help reduce the risk of rejection by the body of organ and bone marrow transplants. Mycophenolate mofetil is a drug used to prevent GVHD after organ transplants. It is also being studied in the prevention of GVHD after stem cell transplants for cancer, and in the treatment of some autoimmune disorders. Mycophenolate mofetil is a type of immunosuppressive agent. Giving emapalumab with post-transplant cyclophosphamide, tacrolimus and mycophenolate mofetil may be safe, tolerable and\u002For effective in preventing GVHD in patients with AML or MDS after a reduced-intensity allogeneic HCT.",[28,29,30],"Acute Myeloid Leukemia","Graft Versus Host Disease","Myelodysplastic Syndrome","RECRUITING","2026-06-29",{"date":34,"type":35},"2026-07-01","ACTUAL",{"date":37,"type":35},"2026-06-12",{"date":39,"type":22},"2027-05-25",{"name":41,"class":42},"City of Hope Medical Center","OTHER",1,{"id":45,"slug":46,"hasResults":12,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":51,"sex":17,"minAge":18,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":56,"conditions":57,"keywords":61,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":4,"leadSponsor":71,"locationsCount":43},"100054545","improved-methods-of-cell-selection-for-bone-marrow-transplant-alternatives-100054545","NCT00001529","Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives","Use of Granulocyte Colony Stimulating Factor (G-CSF) Mobilized Leukapheresis Collections From Healthy Volunteers to Develop Improved Methods of Stem Cell and Lymphocyte Selection for Allogeneic Transplantation","* INCLUSION CRITERIA:\n* Healthy individual aged 18 to 60 years.\n* No active infection or history of recurrent infection.\n* Normal renal function: creatinine \\\u003C1.5 mg\u002FdL or estimated glomerular filtration rate (eGFR) \\>=60 mL\u002Fmin\u002F1.73 m\\^2, with no significant proteinuria.\n\nNormal liver function: bilirubin \\\u003C2.0 mg\u002FdL (when unconjugated), transaminases \\\u003C2.0x ULN in the absence of known liver disease.\n\nNormal blood count: WBC 2,500-11,000\u002Fmicroliter, ANC \\>1,500\u002Fmicroliter, platelets \\>150,000\u002Fmicroliter, hemoglobin \\>12.0 g\u002FdL.\n\n* Normal cardiovascular function, no history of chest pain, myocardial infarction, peripheral vascular disease, transient ischemic attack, or stroke.\n* Healthy female subjects of childbearing age should have a negative serum pregnancy test with one week of beginning G-CSF administration.\n* Female subjects should not be lactating.\n* Subject must be eligible for normal blood donation. He or she must be tested negative for syphilis (RPR), hepatitis B and C (HBsAg, Anti-HBc, Anti-HCV), HIV, HTLV-1, West Nile virus, T. Cruzi and Babesia test.\n* Subject must be able to comprehend the investigational nature of the study and provide informed consent to participate in the protocol.\n* Antecubital veins must be adequate for peripheral access during apheresis. Potential participants must be screened by an apheresis nurse to check venous access before protocol entry.\n\nEXCLUSION CRITERIA:\n\n* Active viral, bacterial, fungal or parasite infection.\n* Female with positive pregnancy test or lactating.\n* Active or moderate-to-severe autoimmune disease that is currently treated or expected to require immunosuppressive therapy. Candidates with stable, well-controlled mild autoimmune disease may be considered on a case-by-case basis.\n* Active or recent malignancy within the past 5 years. Individuals with remote (\\>5 years) histories of low-risk malignancies in remission (e.g., localized prostate cancer) or treated basal cell carcinoma may be included.\n* History of any hematologic disorders.\n* History of clinically significant cardiovascular disease (e.g., symptomatic coronary artery disease, uncontrolled hypertension). Minor risk factors must be evaluated on a case-by-case basis (e.g., controlled hypertension).\n* Any positive serum screening test as listed in eligibility.\n* Allergy to G-CSF or bacterial E coli products.\n* Administration of NSAID within. 5-7 days of starting the protocol, depending on drug half-life.\n* History of G-CSF administration and leukapheresis within past 3 months.",true,"60 Years",{"count":54,"type":22},500,"OBSERVATIONAL","Bone marrow transplants (BMT) are one form of treatment for disorders of the blood, including leukemia. However, because the procedure is often associated with potentially life-threatening reactions, it is usually reserved for patients with serious illnesses under the age of 60 years old.\n\nOne serious reaction complicating bone marrow transplants is referred to as graft-versus-host disease (GVHD). GVHD is a potentially fatal incompatibility reaction. The reaction is caused by antigens found on the cells of the patient that are not present on the cells of the donor. The antigens are recognized by transplanted white blood cells (lymphocytes). These lymphocytes begin attacking the recipient s cells and tissues and may lead to death.\n\nIn order to avoid GVHD, researchers have developed a technique using peripheral blood instead of bone marrow that allows transplantation of stem cells and removal of lymphocytes. Stem cells are the cells responsible for returning blood cell production to normal. Lymphocytes are the white blood cells that can cause GVHD.\n\nThe technique requires two steps. In the first step blood cells are collected from donors who have received doses of a growth factor. The growth factor (granulocyte colony stimulating factor) is designed to increase the production of donor stem cells.\n\nIn the second step white blood cell lymphocytes are removed from the collected blood, leaving only the stem cells.\n\nThe main goal of this study is to develop and improve the method of processing cells that are collected after stimulation with growth factor (G-CSF), by removing the white blood cell lymphocytes which can cause graft-versus-host disease (GVHD) while keeping the stem cells necessary for healthy blood cell building. In addition, researchers are interested in studying whether giving G-CSF has an effect on lymphocyte function, which may influence the immune reactions occurring in bone marrow transplantation.",[58,59,60],"Graft-Versus-Host Disease","Graft-versus-leukemia","Donor Apheresis",[62,60,29,63,64,65],"G-CSF","graft versus leukemia","Natural History","Normal Volunteer","2026-06-27",{"date":68,"type":35},"2026-06-30",{"date":70,"type":35},"1996-03-18",{"name":72,"class":73},"National Heart, Lung, and Blood Institute (NHLBI)","NIH",{"id":75,"slug":76,"hasResults":12,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":81,"targetDuration":4,"studyType":23,"phases":83,"briefSummary":85,"conditions":86,"keywords":89,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":102},"100593443","phase-2-a-study-of-belumosudil-in-people-at-risk-of-developing-graft-versus-host-disease-after-a-stem-cell-transplant-100593443","NCT07006506","A Study of Belumosudil in People at Risk of Developing Graft-Versus-Host Disease After a Stem Cell Transplant","Phase II Open Label Prospective Nonrandomized Trial of Belumosudil for Switch-Maintenance Prophylaxis of Graft-versus-Host Disease in Allogeneic Hematopoietic Cell Transplantation","Inclusion Criteria:\n\n* Patients ≥ 18 years-old at time of consent.\n* Diagnosis: hematologic malignancy in morphologic remission who will be treated with RI or NMA conditioning and GVHD prophylaxis CNI-based (CNI without PTCY) plus abatacept or PTCY-based (CNI with PTCY).\n* Recipients of 7-8\u002F8 related or unrelated HLA-matched or related haploidentical donor.\n* Peripheral blood stem cell graft\n* Allo-HCT day \\\u003C120 at time of consent\n\nPost-HCT inclusion criteria (within 3 weeks before start of belumosudil treatment)\n\n* Patient has received an allo-HCT transplant and is in morphologic remission (blasts \\\u003C5%, no evidence of extramedullary disease in AML or MDS). Patients with CR with incomplete count recovery (CRp or CRi) or minimal residual disease are allowed.\n* Patient has achieved engraftment. Engraftment is defined as ANC≥500\u002FμL and platelets ≥ 20000\u002FμL on 3 consecutive measurements (each occurring at least 1 day apart). The patient must not have had a platelet transfusion within 7 days before the first measurement.\n* Patient is ≥ 80 days and ≤ 20 days from allo-HCT infusion.\n* Karnofsky score ≥ 70%.\n* Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3x upper limit of normal (ULN)\n* Total bilirubin ≤1.5 x ULN (unless benign congenital hyperbilirubinemia).\n* Glomerular filtration rate (GFR) ≥ 30 mL\u002Fmin\u002F1.73 m2\n* Female subjects of childbearing potential (≤ 50 years old) have a negative serum or urine pregnancy test. Females of childbearing potential are defined as females without prior hysterectomy or who have had any evidence of menses in the past 12 months.\n\n  ° Sexually active females of childbearing potential enrolled in the study must agree to consistently use two forms of accepted methods of contraception during the course of the study and for 3 months after their last dose of study drug. Effective birth control includes: \\* Intrauterine device (IUD) plus one barrier method \\* Stable doses of hormonal contraception for at least 3 months (eg, oral, injectable, implant, transdermal) plus one barrier method \\* 2 barrier methods. Effective barrier methods are male or female condoms, diaphragms, and spermicides (creams or gel that contain a chemical to kill sperm); or \\* A vasectomized partner\n* For male subjects who are sexually active and who are partners of females of childbearing potential: Agreement to use two forms of contraception as per above and to not donate sperm during the treatment period and for at least 3 months after the last dose of study drug.\n\nExclusion Criteria:\n\n* Recipient of CD34+ selected or engineered stem cell graft.\n* Treatment with in vivo T cell depletion (e.g. anti-thymocyte globulin).\n* Evidence of current uncontrolled cardiovascular conditions, uncontrolled cardiac arrhythmias, symptomatic congestive heart failure, unstable angina, or myocardial infarction within the past 6 months.\n* Pulmonary dysfunction with DLCO \\\u003C50% corrected for hemoglobin\n* Patients with an active secondary malignancy or prior malignancy requiring systemic therapy within the past 5 years. Exceptions include adequately treated localized non melanoma skin cancer (basal cell carcinoma and squamous cell carcinoma), as well as localized prostate cancer considered low risk and stable under treatment or surveillance.\n\nPost-HCT exclusion criteria\n\n* Uncontrolled infection, including active hepatitis B and C. Definitive therapy for infection is required and must have no signs of progression within 7 days of the first day of study drug treatment.\n* Use of investigational agent within 14 days pre-HCT or anytime thereafter.\n* Active acute or chronic GVHD requiring systemic therapy (topical or local therapies are allowed).\n* Active treatment with corticosteroids at a dose of ≥ 0.25 mg\u002Fkg\u002Fday for non-GVHD indication.\n* Uncontrolled psychosis, active suicidal ideation, or psychiatric hospitalization within the past year\n* Female patient who is pregnant or breastfeeding.\n* Prior therapy with belumosudil.\n* Known allergy or sensitivity to belumosudil or any other ROCK2 inhibitor.",{"count":82,"type":22},46,[84],"PHASE2","The purpose of this study is to find out whether adding belumosudil to a usual approach for reducing the risk of graft-versus-host disease (GVHD) may be an effective GVHD prevention approach for people with blood cancer who have a stem cell transplant. The investigators will also look at the safety of the study approach.",[29,87,88],"Graft Vs Host Disease","Hematologic Malignancy",[29,87,88,90,91,92,93,94],"Hematologic malignancy in morphologic remission","Belumosudil","Stem Cell Transplant","Memorial Sloan Kettering Cancer Center","25-033","2026-06-25",{"date":32,"type":35},{"date":98,"type":35},"2025-05-21",{"date":100,"type":22},"2029-05-21",{"name":93,"class":42},8,{"id":104,"slug":105,"hasResults":12,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":4,"eligibilityCriteria":109,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":110,"enrollmentInfo":111,"targetDuration":4,"studyType":23,"phases":113,"briefSummary":114,"conditions":115,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":119,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":43},"100578723","phase-2-vedolizumab-plus-post-transplant-cyclophosphamide-and-short-course-tacrolimus-for-the-prevention-of-graft-versus-host-disease-in-patients-undergoing-allogeneic-hematopoietic-cell-transplantation-after-reduced-intensity-conditioning-100578723","NCT06815003","Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity Conditioning","Phase-2 Study of Vedolizumab Plus Post-Transplant Cyclophosphamide and Short Course Tacrolimus for Graft-versus-Host Disease Prevention After Reduced Intensity Conditioning Peripheral Blood Stem Cell Allogeneic Hematopoietic Cell Transplantation","Inclusion Criteria:\n\n* Documented informed consent of the participant and\u002For legally authorized representative\n\n  * Assent, when appropriate, will be obtained per institutional guidelines\n* Agreement to allow the use of archival tissue from diagnostic tumor biopsies\n\n  * If unavailable, exceptions may be granted with study principal investigator (PI) approval\n* Age: ≥ 18 and ≤ 80 years old\n\n  * Note: Patients \\> 70 years of age must have Karnofsky performance status ≥ 80 and hematopoietic cell transplantation-comorbidity index (HCT-CI) ≤ 2\n* Karnofsky performance status ≥ 70%\n* Patients with the following diagnosis, eligible to undergo allogeneic HCT from an 8\u002F8 match related\u002Funrelated donor (A, B, C, DR by high resolution typing)\n\n  * Acute Leukemias (acute myeloid leukemia \\[AML\\] or acute lymphoblastic leukemia \\[ALL\\]) in complete remission with bone marrow (BM) blast of \\\u003C 5%\n  * Myelodysplastic syndrome (blast \\\u003C 10%)\n  * Myeloproliferative neoplasm (MPN) other than myelofibrosis (MF) needing HCT\n  * Chronic myelomonocytic leukemia (CMML)\n* Hemoglobin ≥ 9g\u002FdL (within 30 days prior to day 1 of protocol therapy)\n\n  * NOTE: Red blood cell transfusions are not permitted within 14 days of hemoglobin assessment unless cytopenia is secondary to disease involvement\n* Total bilirubin ≤ 2.0 mg\u002FdL (unless has Gilbert's disease) AND serum glutamic oxaloacetic transaminase (SGOT) and serum glutamic pyruvic transaminase (SGPT) \\\u003C 5 times the upper limit of normal (ULN) (within 30 days prior to day 1 of protocol therapy)\n* Aspartate aminotransferase (AST) =\\\u003C 3.0 x ULN (within 30 days prior to day 1 of protocol therapy)\n* Alanine aminotransferase (ALT) =\\\u003C 3.0 x ULN (within 30 days prior to day 1 of protocol therapy)\n* Creatinine clearance of ≤ 1.5 mg\u002FdL or ≥ 60 mL\u002Fmin per 24 hour urine test or the Cockcroft-Gault formula (within 30 days prior to day 1 of protocol therapy)\n* Left ventricular ejection fraction (LVEF) ≥ 50%\n\n  * Note: To be performed within 28 days prior to day 1 of protocol therapy\n* IF ABLE TO PERFORM PULMONARY FUNCTION TESTS: Forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC) and DLCO (diffusion capacity) ≥ 50% of predicted (corrected for hemoglobin)\n\n  * Note To be performed within 28 days prior to day 1 of protocol therapy\n* IF UNABLE TO PERFORM PULMONARY FUNCTION TESTS: Oxygen (O2) saturation \\> 92% on room air\n\n  * Note To be performed within 28 days prior to day 1 of protocol therapy\n* Seronegative for HIV antigen\u002Fantibody (Ag\u002FAb) combo, hepatitis C virus (HCV), active hepatitis B virus (HBV) (surface antigen negative) (within 30 days prior to day 1 of protocol therapy)\n\n  * HIV-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial\n* Tuberculosis test (within 30 days prior to day 1 of protocol therapy)\n\n  * Patients with positive tuberculosis (TB) test results will have infectious disease (ID) evaluation and post HCT therapy with isoniazid (INH) for 6 months with ID follow up. Vaccinated patients will need negative chest X-ray results\n* Meets other institutional and federal requirements for infectious disease titer requirements\n\n  * Note Infectious disease testing to be performed within 28 days prior to day 1 of protocol therapy\n* Women of childbearing potential (WOCBP): Negative urine or serum pregnancy test (within 30 days prior to day 1 of protocol therapy)\n\n  * If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required\n* Agreement by females and males of childbearing potential to use an effective method of birth control or abstain from heterosexual activity for the course of the study through at least 3 months after the last dose of protocol therapy\n\n  * Childbearing potential defined as not being surgically sterilized (men and women) or have not been free from menses for \\> 1 year (women only)\n\nExclusion Criteria:\n\n* Prior allogeneic HCT\n* Chemotherapy, radiation therapy, biological therapy, immunotherapy within 14 days prior to day 1 of protocol therapy\n\n  * Note: Conditioning regimen within 14 days prior to day 1 of protocol therapy is not considered as an exclusion criterion. Patients on maintenance chemotherapy with agents listed are not excluded\n* Other investigational drugs for GVHD prophylaxis\n* Herbal medications\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to study agent\n* Clinically significant uncontrolled illness\n* Active infection not responding to antibiotics\n* Other active malignancy. Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial\n* Females only: Pregnant or breastfeeding\n* Patients not expected to be available for follow-up in our institution for at least 100 days after the transplant\n* Any other condition that would, in the investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns with clinical study procedures\n* Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility\u002Flogistics)","80 Years",{"count":112,"type":22},35,[84],"This phase II trial studies how well vedolizumab plus post-transplant cyclophosphamide (PTCy) and short course tacrolimus work for the prevention of graft versus host disease (GVHD) in patients undergoing allogeneic hematopoietic cell transplantation (HCT) after reduced intensity conditioning. Allogeneic HCT is a procedure in which a person receives blood-forming stem cells (cells from which all blood cells develop) from a donor. Giving reduced conditioning chemotherapy before an allogeneic HCT helps kill cancer cells in the body and helps make room in the patient's bone marrow for new stem cells to grow using less than standard doses of chemotherapy. Sometimes, the transplanted cells from a donor can attack the body's normal cells (called graft-versus-host disease). Vedolizumab is a monoclonal antibody, which is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). It may reduce inflammation. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid and may kill cancer cells. It may also lower the body's immune response. Tacrolimus suppresses the immune system by preventing the activation of certain types of immune cells. Giving vedolizumab plus PTCy and short course tacrolimus may be effective at preventing GVHD after allogeneic HCT.",[116,28,117,29,30,118],"Acute Lymphoblastic Leukemia","Chronic Myelomonocytic Leukemia","Myeloproliferative Neoplasm",{"date":32,"type":35},{"date":121,"type":35},"2025-04-18",{"date":123,"type":22},"2028-10-15",{"name":41,"class":42},{"id":126,"slug":127,"hasResults":12,"nctId":128,"briefTitle":129,"officialTitle":130,"acronym":4,"eligibilityCriteria":131,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":132,"enrollmentInfo":133,"targetDuration":4,"studyType":23,"phases":135,"briefSummary":136,"conditions":137,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":141,"lastUpdatePostDateStruct":142,"startDateStruct":144,"completionDateStruct":146,"leadSponsor":148,"locationsCount":43},"100546267","phase-1-dose-escalation-trial-of-mesenchymal-stromal-cells-in-patients-with-medical-xerostomia-100546267","NCT06392711","Dose-Escalation Trial of Mesenchymal Stromal Cells in Patients With Medical Xerostomia","UW23129: A Phase I Dose-Escalation Trial of Mesenchymal Stromal Cells in Patients With Medical Xerostomia","Inclusion Criteria:\n\n* Xerostomia, defined as an unstimulated salivary flow \\\u003C1.2 mL in 5 minutes documented at any time following xerostomia diagnosis and prior to enrollment\n* Xerostomia not resulting from radiotherapy (medical xerostomia)\n* ≥ 18 years of age, ≤ 90 years of age\n* Karnofsky performance status ≥ 70, patient eligible for bone marrow aspirate with wakeful anesthesia\n* Willing and able to give informed consent\n* Radiographically confirmed bilateral submandibular glands\n* If female of childbearing potential, negative pregnancy test\n* Males and females of childbearing potential willing to use acceptable contraception\n* Laboratory Values (within 28 calendar days of enrollment):\n\n  * Hgb ≥ 9 g\u002FdL (5.58 mmol\u002FL)\n  * Platelets ≥ 100,000\u002FµL\n  * ANC ≥ 1000\u002FµL\n  * Lymphocytes ≥ 800\u002FµL\n  * PT\u002FINR and PTT within normal limits based on age\u002Fsex\n\nExclusion Criteria:\n\n* Patients with one submandibular gland\n* Sialolithiasis\n* Poorly-controlled diabetes mellitus (HbA1c ≥ 7%)\n* Patients who initiated any diuretic therapy before developing dry mouth symptoms and are still on diuretic therapy and the referring provider believes the dryness symptoms are driven by diuretic use\n* Untreated oral candidiasis based on physical exam at enrollment\n* Malignancy within the last 2 years (except adequately treated stage I lung cancer, low risk prostate cancer that has been treated or is undergoing active surveillance, adequately treated non-melanoma skin cancer, adequately treated DCIS, or adequately treated stage I cervical cancer)\n* For patients on immunosuppressive therapy, must be on stable dose of immunosuppressive therapy for at least 2 months, allowing for dose adjustments for blood levels of drugs\n* Transfusion dependency\n* Life expectancy ≤ 6 months as determined by the investigator\n* Use of investigational drugs, biologics, or devices within 30 calendar days prior to enrollment\n* Pregnant or lactating women or those who plan to become pregnant during the study\n* Not suitable for study participation due to other reasons at discretion of investigators.\n* Enrollment in another clinical study possibly interfering with the endpoints of this study","90 Years",{"count":134,"type":22},36,[25],"The goal of this clinical trial is to evaluate the safety and tolerability of injecting certain cells produced in bone marrow called mesenchymal stromal cells (MSCs) into salivary glands. The main question it aims to answer is whether injection of MSCs into salivary glands results in any improvement in dry mouth.\n\nParticipants will:\n\n* have bone marrow collected using a needle\n* undergo a salivary gland ultrasound\n* complete questionnaires\n* receive an injection of the bone marrow cells into a salivary gland",[138,139,140],"Xerostomia","Graft-versus-host-disease","Sjogren's Disease","2026-06-17",{"date":143,"type":35},"2026-06-22",{"date":145,"type":35},"2024-10-04",{"date":147,"type":22},"2028-11",{"name":149,"class":42},"University of Wisconsin, Madison",{"id":151,"slug":152,"hasResults":12,"nctId":153,"briefTitle":154,"officialTitle":155,"acronym":4,"eligibilityCriteria":156,"healthyVolunteers":12,"sex":17,"minAge":157,"maxAge":4,"enrollmentInfo":158,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":160,"conditions":161,"keywords":162,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":166,"startDateStruct":168,"completionDateStruct":170,"leadSponsor":172,"locationsCount":43},"100643400","a-study-of-ruxolitinib-in-patients-with-graft-versus-host-disease-100643400","NCT07594587","A Study of Ruxolitinib in Patients With Graft-Versus Host Disease","Post-marketing Database Study in Patients With Graft-Versus Host Disease for JAKAVI Tablets","Inclusion Criteria:\n\n* Patients with acute and chronic GVHD\n* Patients treated with ruxolitinib\n\nExclusion Criteria:\n\nNone\n\nOther protocol-defined inclusion\u002Fexclusion criteria may apply.","0 Years",{"count":159,"type":22},395,"This study aims to evaluate the safety and effectiveness of Jakavi® (ruxolitinib) in patients with acute graft-versus host disease (GVHD) and chronic GVHD in clinical practice.",[58],[163,164],"Ruxolitinib","GVHD","2026-06-05",{"date":167,"type":35},"2026-06-08",{"date":169,"type":35},"2026-05-11",{"date":171,"type":22},"2030-05-15",{"name":173,"class":174},"Novartis Pharmaceuticals","INDUSTRY",{"id":176,"slug":177,"hasResults":12,"nctId":178,"briefTitle":179,"officialTitle":180,"acronym":4,"eligibilityCriteria":181,"healthyVolunteers":12,"sex":17,"minAge":182,"maxAge":183,"enrollmentInfo":184,"targetDuration":4,"studyType":23,"phases":186,"briefSummary":187,"conditions":188,"keywords":190,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":192,"lastUpdatePostDateStruct":193,"startDateStruct":195,"completionDateStruct":197,"leadSponsor":199,"locationsCount":43},"100461477","phase-1-post-transplant-cyclophosphamide-bortezomib-and-abatacept-for-the-prevention-of-graft-versus-host-disease-gvhd-100461477","NCT05289167","Post-Transplant Cyclophosphamide, Bortezomib and Abatacept for the Prevention of Graft-versus-Host-Disease (GvHD)","A Phase I-II Study of High-Dose Post-Transplant Cyclophosphamide, Bortezomib and Abatacept for the Prevention of Graft-versus-Host-Disease (GvHD) Following Allogenic Hematopoietic Stem Cell Transplantation (HSCT)","Inclusion Criteria:\n\n* Age ≥14 years\n* Karnofsky score ≥70%\n* No evidence of progressive bacterial, viral, or fungal infection\n* Creatinine clearance \\>50 mL\u002Fmin\u002F1.72m2\n* ALT and AST \\\u003C3 x the upper limit of normal\n* Total bilirubin \\\u003C2 x the upper limit of normal (except for Gilbert's syndrome)\n* Alkaline phosphatase ≤250 IU\u002FL\n* Left Ventricular Ejection Fraction (LVEF) \\>45%\n* Adjusted Carbon Monoxide Diffusing Capacity (DLCO) \\>50%\n* Negative HIV serology\n* Negative pregnancy test: Confirmation per negative serum β-human chorionic gonadotropin (β-hCG)\n* Willing to comply with all study procedures and be available for the duration of the study.\n\nExclusion Criteria:\n\n* Pregnant or nursing females or women of reproductive capability who are unwilling to completely abstain from heterosexual sex or practice 2 effective methods of contraception from start of conditioning through 90 days after the last dose of study drug. A woman of reproductive capability is one who has not undergone a hysterectomy (removal of the womb), has not had both ovaries removed, or has not been post-menopausal (stopped menstrual periods) for more than 24 months in a row.\n* Male subjects who refuse to practice effective barrier contraception from the start of conditioning through a minimum of 90 days after the last dose of study drug, or completely abstain from heterosexual intercourse. This must be done even if they are surgically sterilized (i.e., post-vasectomy).\n* Inability to provide informed consent.\n* Patient had myocardial infarction within 6 months prior to enrollment or has New York Heart Association (NYHA) Class III or IV heart failure (see Appendix D), uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities. Prior to study entry, any ECG abnormality at screening must be documented by the investigator as not medically relevant.\n* Known allergies to any of the components of the investigational treatment regimen.\n* Serious medical or psychiatric illness likely to interfere with participation in this clinical study.\n* Diagnosed or treated for another malignancy within 3 years of enrollment, with the exception of complete resection of basal cell carcinoma or squamous cell carcinoma, an in-situ malignancy, or low-risk prostate cancer after curative therapy.\n* Participation in clinical trials with other investigational agents not included in this trial, within 14 days of the start of this trial and throughout the duration of this trial.\n* Prisoners\n* Pregnant women","14 Years","100 Years",{"count":185,"type":22},74,[25,84],"This is a phase I-II clinical trial. Adult subjects with hematological malignancies undergoing allogeneic HSCT from an HLA matched sibling or ≥7 out of 8 allele level HLA matched unrelated donor are eligible for the study if they meet the criteria defined in our standard operation procedures (SOPs), meet all inclusion criteria, and do not satisfy any exclusion criteria. Subjects will receive a standard of care conditioning regimen. Subjects will receive investigational PTCy, investigational bortezomib and investigational abatacept as GvHD prophylaxis.",[189],"Graft-versus-host Disease",[191],"GvHD, post transplant cyclophosphamide, abatacept","2026-05-26",{"date":194,"type":35},"2026-05-29",{"date":196,"type":35},"2022-03-13",{"date":198,"type":22},"2028-08",{"name":200,"class":42},"Northwell Health",{"id":202,"slug":203,"hasResults":12,"nctId":204,"briefTitle":205,"officialTitle":206,"acronym":4,"eligibilityCriteria":207,"healthyVolunteers":51,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":208,"targetDuration":4,"studyType":23,"phases":210,"briefSummary":211,"conditions":212,"keywords":4,"overallStatus":215,"whyStopped":4,"lastUpdateSubmitDate":216,"lastUpdatePostDateStruct":217,"startDateStruct":219,"completionDateStruct":221,"leadSponsor":223,"locationsCount":43},"100639818","phase-1-evaluating-the-effects-of-propionate-and-butyrate-supplementation-on-the-intestinal-health-of-healthy-volunteers-100639818","NCT07611370","Evaluating the Effects of Propionate and Butyrate Supplementation on the Intestinal Health of Healthy Volunteers","A Pilot Feasibility Study of Oral Administration of Microencapsulated Propionate and Butyrate in Healthy Volunteers","Inclusion Criteria:\n\n* Documented informed consent of the participant and\u002For legally authorized representative\n* Age: ≥ 18 years and ≤ 75 years old\n* Ability to read and understand and willingness to sign a written informed consent\n* Ability to understand English to fill out required forms (e.g. Pill Diary and Symptom Diary)\n* Participants are not taking butyrate or propionate as supplement(s)\n\n  * Those who are already taking butyrate or propionate as supplement(s) are allowed only if they are willing to stop the supplement(s) ≥ 7 days prior to baseline samples and for the duration of this study\n\nExclusion Criteria:\n\n* History of migraines and chronic gastrointestinal diseases, such as inflammatory bowel disease or Crohn's disease\n* History of allergic reactions to compounds of similar chemical or biologic composition to study agent\n* Females only: Pregnant, breastfeeding, or planning to get pregnant\n* Antibiotic exposure within 2 weeks prior to day 1 of study",{"count":209,"type":22},12,[25],"This clinical trial evaluates how propionate and butyrate supplementation alters intestinal health in healthy volunteers and whether it would be feasible to administer these supplements to patients undergoing allogeneic hematopoietic stem cell transplant in the future. Propionate and butyrate are short chain fatty acids naturally produced in the intestines during the fermentation of dietary fibers. Greater levels of propionate and butyrate may improve intestinal barrier function, and propionate specifically has been shown to modulate immunity, energy metabolism, and gut-brain communication. The protective effects of propionate and butyrate supplementation on intestinal health may be especially beneficial for patients undergoing donor stem cell transplant, as these patients can experience significant gastrointestinal injury during treatment. The results of this study may help researchers determine whether propionate and butyrate supplementation positively alters the gut microbiome and whether or not supplementation could be used in the future for patients undergoing a donor stem cell transplant.",[29,213,214],"Hematopoietic and Lymphatic System Neoplasm","Malignant Solid Neoplasm","NOT_YET_RECRUITING","2026-05-20",{"date":218,"type":35},"2026-05-28",{"date":220,"type":22},"2026-09-30",{"date":222,"type":22},"2027-06-30",{"name":41,"class":42},{"id":225,"slug":226,"hasResults":12,"nctId":227,"briefTitle":228,"officialTitle":229,"acronym":4,"eligibilityCriteria":230,"healthyVolunteers":12,"sex":17,"minAge":231,"maxAge":4,"enrollmentInfo":232,"targetDuration":4,"studyType":23,"phases":234,"briefSummary":235,"conditions":236,"keywords":238,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":216,"lastUpdatePostDateStruct":242,"startDateStruct":244,"completionDateStruct":246,"leadSponsor":248,"locationsCount":249},"100491192","phase-2-a-study-of-photobiomodulation-pbm-therapy-in-people-with-oral-graft-versus-host-disease-gvhd-after-stem-cell-transplant-100491192","NCT05675930","A Study of Photobiomodulation (PBM) Therapy in People With Oral Graft-Versus-Host Disease (GVHD) After Stem Cell Transplant","A Multi-Center, Phase II, Randomized Double-Blind Trial to Evaluate the Efficacy and Safety of Photobiomodulation for the Treatment of Oral Chronic Graft-Versus-Host Disease After Allogeneic Stem Cell Transplantation (the LIGHT Trial)","Inclusion Criteria:\n\n* Allo-HCT recipients\n* Age ≥ 4 years-old\n* Oral cGvHD with NIH-modified OMRS score ≥ 3 who have failed ≥ 1 line of therapy, including topical corticosteroids..\n* No change in systemic immunosuppressive therapy (type or intensity level) within 2 weeks prior to enrollment.\n* If a patient is currently using another oral topical treatment for mouth lesions\u002Fsymptoms, patient must be stable on this treatment for ≥2 weeks prior to study enrollment. Patient may continue same topical dose\u002Ffrequency during the study period.\n\nExclusion Criteria:\n\n* Presence of an active uncontrolled infection. Subjects with a controlled infection receiving definitive therapy for 48 hours prior to enrollment are eligible.\n* Personal history of mucosal head and neck cancer in the past 5 years.\n* Pregnant or breastfeeding.\n* The subject or guardian is unable to give informed consent or unable to comply with the treatment protocol including appropriate supportive care, follow-up, and research tests.\n* Any serious medical or psychiatric illness that could, in the Investigator's opinion, potentially interfere with the completion of treatment according to this protocol.","4 Years",{"count":233,"type":22},44,[84],"The purpose of this study is to find out whether photobiomodulation\u002FPBM therapy using the Thor LX2.3 therapy system is a safe and effective treatment for oral Graft-Versus-Host Disease\u002FGVHD.",[58,164,237],"Undefined",[58,164,239,240,93,241],"Chronic Graft Versus Host Disease Oral","PhotobiomoduLatIon","22-271",{"date":243,"type":35},"2026-05-22",{"date":245,"type":35},"2022-12-22",{"date":247,"type":22},"2026-12-22",{"name":93,"class":42},9,{"id":251,"slug":252,"hasResults":12,"nctId":253,"briefTitle":254,"officialTitle":255,"acronym":4,"eligibilityCriteria":256,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":257,"enrollmentInfo":258,"targetDuration":4,"studyType":23,"phases":260,"briefSummary":261,"conditions":262,"keywords":269,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":169,"lastUpdatePostDateStruct":272,"startDateStruct":274,"completionDateStruct":276,"leadSponsor":278,"locationsCount":43},"100636491","phase-2-cord-blood-transplantation-in-children-and-young-adults-with-blood-cancer-100636491","NCT07566377","Cord Blood Transplantation in Children and Young Adults With Blood Cancer","Cord Blood Transplantation in Children and Young Adults With Hematologic Malignancies","Inclusion Criteria:\n\nA patient cannot be considered eligible for this study unless ALL of the following conditions are met.\n\n° Disease type\n\nCohort 1, High Risk Disease: Patients with age ≤ 26 years at the time of informed consent with no available and suitably matched related or unrelated donor within 4 weeks, with one of the following diagnoses:\n\nI. Acute myelogenous leukemia (AML):\n\n* Complete first remission (CR1) with blast count \\\u003C 5% by bone marrow morphology at high risk for relapse such as any of the following:\n\n  * Known prior diagnosis of myelodysplasia (MDS)\n  * High risk cytogenetics (e.g., those associated with MDS, abnormalities of 5, 7, 8, complex karyotype) and\u002For high-risk molecular abnormalities (e.g., TP53)\n  * Requirement for 2 or more inductions to achieve CR1\n  * Therapy-related AML (t-AML) or therapy-related myeloid neoplasm (t-MN) (including after therapy for other malignancy, and\u002For gene therapy or cell therapy)\n  * Presence of Minimal\u002FMeasurable Residual Disease (MRD+) by cytogenetics, flow cytometry or molecular methods (at End of Induction or End of Consolidation)\n  * Other high-risk features not defined above.\n* Complete second remission (CR2) or subsequent remission, with blast count \\\u003C 5% by bone marrow morphology\n* Presence of MRD by multiparameter flow cytometry at pre-transplant evaluation is acceptable.\n\nII. Acute lymphoblastic leukemia (ALL):\n\n* Complete first remission (CR1) with MRD negative status by multicolor flow cytometry, at high risk for relapse such as any of the following:\n\n  * Presence of any high risk cytogenetic abnormalities such as t(9;22), t(1;19), t(4;11) or other, KMT2A (11q23) or other high risk molecular abnormality\n  * Failure to achieve complete remission (CR) after four weeks of induction therapy (transplant to follow antibody therapy and\u002For CAR T cells)\n  * Persistence or recurrence of MRD on therapy (Transplant to follow antibody therapy and\u002For CAR T cells)\n  * T-ALL in CR even with presence of MRD\n  * Other high-risk features not defined above\n* Complete second remission (CR2) or subsequent remission with MRD negative status by multiparameter flow cytometry.\n\n  * Relapse in less than 36 months from CR1\n  * Relapse for T-ALL\n* Patients after antibody therapy (e.g., blinatumomab, inotuzumab, other) and\u002For CAR-T cell therapy that resulted in MRD negative status by multiparameter flow cytometry.\n\nIII. Other acute leukemias:\n\n* Leukemias of ambiguous lineage or of other types with \\\u003C 5% blasts by bone marrow morphology.\n* Patients with persistent\u002Frelapsed disease with cytogenetic, flow cytometric or molecular aberrations in \\\u003C 5% of cells.\n* Chronic myelogenous leukemia: Patients with history of blast crisis or accelerated phase.\n* Any leukemia that developed after gene therapy or cell therapy\n\nIV. Myelodysplastic Syndrome (MDS):\n\n* Any IPSS risk category with life-threatening cytopenia(s).\n* Any IPSS risk category with high risk cytogenetic\u002Fmolecular findings (5, 7, 8, complex karyotype, or TP53)\n\nV. Non-Hodgkin lymphoma (NHL) or Hodgkin lymphoma (HL) at high risk of relapse or progression if not in remission:\n\n* Patients with aggressive histology (such as, but not limited to, diffuse large B-cell NHL, mantle cell NHL, and T-cell NHL) in CR.\n* Patients with indolent B cell NHL (such as, but not limited to, follicular, small cell or marginal zone NHL) will have 2nd or subsequent progression with stable disease\u002F CR\u002F PR with no single lesion equal to or more than 5 cm.\n* Patients with HL without progression of disease (POD) after salvage chemotherapy with no single lesion ≥5 cm.\n\nCohort 2: Very High-Risk disease:\n\n1. Patients in CR (bone marrow blasts \\\u003C5% by morphology) who had prior allogeneic transplant and disease recurrence. The second transplant will take place at least 4 months after the first.\n\n   * Acute myelogenous leukemia (AML) or Myelodysplastic Syndrome (MDS): Relapse after previous transplant, in CR after induction therapy. MRD positive status by multi-parameter flow cytometry is accepted.\n   * Acute lymphoblastic leukemia (ALL): Relapse after previous transplant, in CR after induction therapy and\u002For antibody therapy\u002FCAR T cells. MRD positive status after targeted therapy, as evaluated by multi-parameter flow cytometry is accepted.\n   * Other: patients with leukemia or lymphoma, who, in the opinion of their physician, are not likely to have reduction in disease burden with further chemotherapy.\n2. Patients with relapsed\u002Frefractory disease at either first or second allogeneic transplant, with up to 30% bone marrow blasts by multiparameter flow cytometry or morphology. ° Relapse after previous transplant with \\\u003C 30% blasts by bone marrow morphology, or with cytogenetic, flow cytometric, or molecular abnormalities in \\\u003C 30% of bone marrow cells, after induction therapy.\n\n   ° Primary refractory or relapsed AML with \\\u003C 30% blasts by bone marrow morphology or with cytogenetic, flow cytometric, or molecular abnormalities in \\\u003C 30% of bone marrow cells.\n\n   ° Age 0-26 years at the time of informed consent\n\n   ° Performance: Karnofsky (≥16 years) or Lansky score (\\\u003C16 years) of ≥70% (see Appendix A).\n\n   ° Not Pregnant and Not Nursing\n\n   ° Required Organ Function\n   * Bilirubin ≤ 1.5 mg\u002FdL (unless benign congenital hyperbilirubinemia).\n   * ALT ≤ 3 x upper limit of normal.\n   * Pulmonary function (FVC, FEV1 and DLCO corrected for hemoglobin) ≥ 50% predicted.\n\n     * In young children unable to perform pulmonary function testing: pulse oximetry \\>92% in room air, and a normal CT of the chest (if CT is not normal, the child needs to be evaluated and cleared by pediatric pulmonary physician).\n   * Left ventricular ejection fraction \\> 50%.\n   * Age-adjusted Hematopoietic Cell Transplantation-Comorbidity Index (aaHCT-CI) ≤ 7.\n   * Female patients of childbearing potential must have a negative serum pregnancy test within 7 days of enrolment and must be willing to use an effective contraceptive method while enrolled in the study.\n   * Renal: Serum creatinine (SCr) ≤ 1.5 x normal for age. If SCr is outside the normal range, then CrCl \\> 50 mL\u002Fmin (calculated or estimated) or estimated GFR (mL\u002Fmin\u002F1.73m2) \\>30% of predicted normal for age.\n\n   Normal GFR by Age : Mean GFR +- SD (mL\u002Fmin\u002F1.73m\\^2) 1 week : 40.6 + \u002F - 14.8 2-8 weeks : 65.8 + \u002F - 24.8 \\>8 weeks : 95.7 + \u002F - 21.7 2-12 years : 133.0 + \u002F - 27.0 13-21 years (males) : 140.0 + \u002F - 30.0 13-21 years (females) : 126.0 + \u002F - 22.0\n\n   GFR, glomerular filtration rate; SD, standard deviation; Greater than 2 years old: Normal GFR is 100 mL\u002F min; Infants: GFR must be corrected for body surface area.\n\n   Exclusion Criteria:\n\n   Exclusion criteria for both cohorts:\n\n   ° Inadequate performance status\u002F organ function.\n\n   ° Active CNS leukemic involvement.\n   * Chloroma \\>2 cm.\n   * Active and uncontrolled infection (bacterial\u002Ffungal\u002Fviral) at time of transplant.\n   * HIV infection.\n   * Seropositivity for HTLV-1.\n   * Pregnancy or breast feeding.\n   * Patient or guardian unable to give informed consent or unable to comply with the treatment protocol including appropriate supportive care, long-term follow-up, and research tests.\n   * Any abnormal condition or lab result that is considered by the PI capable or altering patient's condition or study outcome.\n\n   Cohort 2 Very High-Risk Disease (additional to above):\n\n   ° Allogeneic HCT in the preceding 4 months.\n\n   Note (1): Prior checkpoint inhibitors\u002Fblockade in the last 12 months: eligibility to be discussed with study PI.\n\n   Note (2): For patients with known HBV and\u002For HCV infection :\n   * For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated.\n   * Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load.","26 Years",{"count":259,"type":22},71,[84],"The purpose of this study is to find out whether Cord Blood Transplantation\u002FCBT as the first or second transplant is an effective treatment for children and young adults with blood cancer.",[263,116,264,265,266,267,268,189],"Acute Myelogenous Leukemia","Myelodysplastic Syndromes","Non-hodgkin Lymphoma","Hodgkin Lymphoma","Leukemia","Lymphoma",[270,189,268,267,266,265,264,116,263,93,271],"Cord blood transplants","26-168",{"date":273,"type":35},"2026-05-14",{"date":275,"type":35},"2026-04-28",{"date":277,"type":22},"2030-04-28",{"name":93,"class":42},{"id":280,"slug":281,"hasResults":12,"nctId":282,"briefTitle":283,"officialTitle":284,"acronym":4,"eligibilityCriteria":285,"healthyVolunteers":12,"sex":17,"minAge":182,"maxAge":286,"enrollmentInfo":287,"targetDuration":4,"studyType":23,"phases":289,"briefSummary":290,"conditions":291,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":295,"lastUpdatePostDateStruct":296,"startDateStruct":298,"completionDateStruct":300,"leadSponsor":302,"locationsCount":43},"100636975","phase-2-moxibustion-for-steroid-refractory-acute-graft-versus-host-disease-after-allogeneic-hematopoietic-stem-cell-transplantation-100636975","NCT07572669","Moxibustion for Steroid-Refractory Acute Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation","A Prospective, Multicenter, Open-Label, Phase II Study to Evaluate the Safety and Efficacy of Moxibustion in Patients With Steroid-Refractory Acute Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation","Inclusion Criteria:\n\n* Participants must meet all of the following criteria:\n\nAge 14 to 65 years, male or female. Underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT). Diagnosis of acute graft-versus-host disease (aGVHD) according to standard criteria, with gastrointestinal involvement (e.g., abdominal pain and diarrhea), and classified as grade II-IV.\n\nSteroid-refractory or steroid-dependent aGVHD, defined as:\n\nDisease progression within 3 days of systemic corticosteroid treatment, or No response within 7 days, or Failure to achieve complete response after 28 days of immunosuppressive therapy, or Recurrence or worsening during steroid tapering. Absolute neutrophil count ≥ 0.5 × 10⁹\u002FL for at least 3 consecutive days. Traditional Chinese medicine (TCM) syndrome differentiation consistent with spleen-kidney yang deficiency.\n\nFemale participants of childbearing potential must have a negative pregnancy test at screening and agree to use effective contraception during the study.\n\nMale participants must agree to use effective contraception during the study. Ability to understand and willingness to sign a written informed consent form. Willingness and ability to comply with study procedures and follow-up.\n\nExclusion Criteria:\n\n* Participants meeting any of the following criteria will be excluded:\n\nPrior treatment with ≥1 systemic therapy for aGVHD other than corticosteroids. Diagnosis of GVHD overlap syndrome according to NIH criteria. History of splenectomy after transplantation. Evidence of relapse of the underlying disease or receipt of anti-relapse therapy after transplantation.\n\nUnresolved toxicities or complications from prior transplantation (excluding GVHD).\n\nPrior moxibustion therapy after transplantation. Uncontrolled active infection. Known human immunodeficiency virus (HIV) infection. Active hepatitis B or C infection requiring treatment, or risk of HBV reactivation.\n\nReceipt of other investigational therapy within 21 days prior to enrollment (or within 5 half-lives, whichever is longer).\n\nRenal dysfunction: serum creatinine ≥ 2.0 mg\u002FdL or creatinine clearance \\\u003C 40 mL\u002Fmin.\n\nHepatic dysfunction unrelated to GVHD, including cholestatic disease or unresolved hepatic veno-occlusive disease.\n\nSevere cardiovascular disease, including unstable angina, myocardial infarction within 6 months, NYHA class III-IV heart failure, or circulatory failure requiring vasoactive support.\n\nSevere respiratory disease requiring mechanical ventilation or ≥50% oxygen support.\n\nUse of high-dose corticosteroids (≥1 mg\u002Fkg\u002Fday methylprednisolone or equivalent) for non-GVHD indications within 7 days prior to enrollment.\n\nPregnant or breastfeeding women. Severe skin damage or known allergy\u002Fintolerance to study-related procedures. Any other condition that, in the investigator's judgment, would interfere with study participation.","65 Years",{"count":288,"type":22},42,[84],"This study is a prospective, multicenter, open-label, phase II clinical trial designed to evaluate the safety and efficacy of moxibustion in patients with steroid-refractory acute graft-versus-host disease (SR-aGVHD) following allogeneic hematopoietic stem cell transplantation (allo-HSCT).\n\nA total of 42 patients with SR-aGVHD, primarily involving the gastrointestinal tract and presenting with abdominal pain and diarrhea, will be enrolled. All participants will receive standard second-line therapy based on best available treatment (BAT), including ruxolitinib, basiliximab, or methotrexate, according to clinical judgment. In addition, patients will receive moxibustion at specific acupoints (Tianshu \\[ST25\\], Shenque \\[CV8\\], and Qihai \\[CV6\\]) for 30 minutes once or twice daily for 28 days.\n\nThe primary endpoint is the overall response rate (ORR) at Day 28. Secondary endpoints include durable ORR at Day 56, incidence and severity of chronic GVHD (cGVHD), non-relapse mortality (NRM), overall survival (OS), and changes in traditional Chinese medicine (TCM) syndrome scores. Safety will be assessed by monitoring adverse events throughout the study period.\n\nThis study aims to explore whether moxibustion, as an adjunctive therapy, can improve clinical outcomes and provide a safe and effective treatment strategy for patients with SR-aGVHD after allo-HSCT.",[292,293,58,294],"Steroid-Refractory Acute Graft-Versus-Host Disease","Acute Graft-Versus-Host Disease","Allogeneic Hematopoietic Stem Cell Transplantation","2026-05-03",{"date":297,"type":35},"2026-05-07",{"date":299,"type":35},"2025-09-01",{"date":301,"type":22},"2027-09",{"name":303,"class":42},"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology",{"id":305,"slug":306,"hasResults":12,"nctId":307,"briefTitle":308,"officialTitle":309,"acronym":4,"eligibilityCriteria":310,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":311,"targetDuration":4,"studyType":23,"phases":313,"briefSummary":314,"conditions":315,"keywords":316,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":319,"lastUpdatePostDateStruct":320,"startDateStruct":322,"completionDateStruct":324,"leadSponsor":326,"locationsCount":43},"100516767","phase-1-ruxolitinib-with-and-without-ctla-4-ig-abatacept-for-the-prophylaxis-of-graft-versus-host-disease-and-cytokine-release-syndrome-after-t-cell-replete-haploidentical-peripheral-blood-hematopoietic-cell-transplantation-100516767","NCT06008808","Ruxolitinib With and Without CTLA-4 Ig Abatacept for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation","An Open-Label Phase I Study of JAK Inhibitor Ruxolitinib With and Without CTLA-4 Ig Abatacept for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation","Inclusion Criteria:\n\nPatients must meet the following criteria within 30 days prior to Day -3 unless otherwise noted.\n\n* Diagnosis of one of the hematological malignancies listed below:\n\n  * Acute myelogenous leukemia (AML) in complete morphological remission, complete remission with incomplete hematologic recovery, and complete remission with partial hematologic recovery (based on ELN Criteria47).\n  * Acute lymphocytic leukemia (ALL) in complete morphological remission (MRD negative by flow cytometry with sensitivity to ≤ 10-4).\n  * Myelodysplastic syndrome with ≤ 10% blasts in bone marrow.\n  * Non-Hodgkin lymphoma (NHL) or Hodgkin lymphoma (HD) in second or greater complete or partial remission.\n  * Myelofibrosis with ≤ 10% blasts in bone marrow. Up to five patients with myelofibrosis will be permitted in Regimen 1 and up to five in Regimen 2.\n  * AML in partial response. One patient will be enrolled in Regimen 1 given the prospect of potential benefit.\n* Planned treatment is T cell-replete peripheral blood haploidentical donor transplantation.\n* Available HLA-haploidentical donor who meets the following criteria:\n\n  * Blood-related family member, including (but not limited to) sibling, offspring, cousin, nephew, or parent. Younger donors should be prioritized.\n  * At least 18 years of age.\n  * HLA-haploidentical donor\u002Frecipient match by at least low-resolution typing per institutional standards.\n  * In the investigator's opinion, is in general good health and medically able to tolerate leukapheresis required for harvesting hematopoietic stem cells.\n  * No active hepatitis.\n  * Negative for HTLV and HIV.\n  * Not pregnant.\n  * Donor selection will be in compliance with FDA guidelines as provided in 21 CFR 1271 for donor eligibility https:\u002F\u002Fwww.fda.gov\u002Fdownloads\u002FBiologicsBloodVaccines\u002FGuidanceComplianceRegulatoryInformation\u002FGuidances\u002FTissue\u002FUCM091345.pdf\n* Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2.\n* Adequate organ function as defined below:\n\n  * Total bilirubin ≤ 1.5 x IULN.\n  * AST (SGOT) and ALT (SGPT) ≤ 3.0 x IULN.\n  * Creatinine ≤ 1.5 x IULN OR creatinine clearance ≥ 45 mL\u002Fmin\u002F1.73 m2 by Cockcroft-Gault Formula.\n  * Oxygen saturation ≥ 90% on room air.\n  * LVEF ≥ 40%.\n  * FEV1 and FVC ≥ 40% predicted, DLCOc ≥ 40% predicted. If DLCO is \\\u003C 40%, patients will still be considered eligible if deemed safe after a pulmonary evaluation.\n* Able to receive GVHD prophylaxis with tacrolimus, mycophenolate mofetil (if applicable), and cyclophosphamide.\n* At least 18 years of age at the time of study consent\n* The effects of ruxolitinib and abatacept on the developing human fetus are unknown. Additionally, tacrolimus may increase risk of hypertension, preeclampsia, preterm birth, and low birth weight; and mycophenolate mofetil is considered to be teratogenic. For this reason, women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control, abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she must inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study and for the duration of the study.\n* Able to understand and willing to sign an IRB approved written informed consent document (or that of legally authorized representative, if applicable).\n\nExclusion Criteria:\n\n* Prior allogeneic transplant (regardless of whether donor was related, unrelated, or cord). Prior autologous transplant is not exclusionary.\n* Presence of donor specific antibodies (DSA) with Mean Fluorescence Intensity (MFI) of ≥ 4000 as assessed by the single antigen bead assay.\n* Known HIV or active hepatitis B or C infection. Known current history of active tuberculosis.\n* Known hypersensitivity to one or more of the study agents.\n* Planning to receive antithymocyte globulin as part of the pre-transplant conditioning regimen.\n* Currently receiving or has received any investigational drugs within the 14 days prior to the first dose of study drug (Day -3).\n* Pregnant and\u002For breastfeeding. Women of childbearing potential must have a negative pregnancy test within 14 days of Day -3.\n* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, autoimmune disease, symptomatic congestive heart failure, unstable angina pectoris, or unstable cardiac arrhythmias.\n* Immunosuppressive doses of steroids. Subjects with steroids for adrenal insufficiency will not be excluded.",{"count":312,"type":22},41,[25],"Allogeneic hematopoietic cell transplantation (HCT) is one of the only curative intent therapies available for hematologic malignancies. HLA-matched sibling donors have historically offered the best clinical results but are unavailable for the majority of patients, while most patients do have readily available haploidentical donors. One of the risks of a haploidentical HCT is graft vs. host disease (GVHD), but it is difficult to reduce the incidence of GVHD without compromising the graft vs. leukemia (GVL) effect.\n\nThe hypothesis of this study is that JAK inhibition with and without CTLA-4 Ig with haploidentical HCT may mitigate GVHD and cytokine release syndrome while retaining the GVL effect and improving engraftment.",[87,139,29],[317,164,318],"Haploidentical","CRS","2026-04-21",{"date":321,"type":35},"2026-04-22",{"date":323,"type":35},"2024-05-07",{"date":325,"type":22},"2027-11-27",{"name":327,"class":42},"Washington University School of Medicine",{"id":329,"slug":330,"hasResults":12,"nctId":331,"briefTitle":332,"officialTitle":333,"acronym":4,"eligibilityCriteria":334,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":335,"targetDuration":4,"studyType":23,"phases":336,"briefSummary":337,"conditions":338,"keywords":346,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":351,"lastUpdatePostDateStruct":352,"startDateStruct":354,"completionDateStruct":356,"leadSponsor":358,"locationsCount":43},"100620332","phase-2-ruxolitinib-maintenance-post-hematopoietic-stem-cell-transplant-t-cell-lymphoma-100620332","NCT07356245","Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma","Phase II Study of Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant in T-Cell Lymphoma","Inclusion Criteria:\n\n1. Adult patients with T-cell lymphoma \\[PTCL (all subtypes), T-PLL, ATLL, and CTCL (all subtypes)\\] in partial or complete remission between day +35 and +120 from auto-SCT or allo-SCT\n2. Eastern Cooperative Oncology Group (ECOG) performance status of 2 or less\n3. Adequate hematologic function defined by absolute neutrophil count (ANC) \\> 1000\u002Fmm3 without granulocyte colony-stimulating factor (G-CSF) for at least 3 days, platelets \\> 50K\u002Fmm3 without transfusion for at least 3 days and hemoglobin (Hb) \\> 8.0 g\u002FdL without transfusion for at least 3 days.\n4. Adequate organ function defined by total Bilirubin \\\u003C 1.5 x ULN, alanine aminotransferase (ALT) \\\u003C\u002F= 3 x ULN, CKD-EPI eGFR ≥ 30 ml\u002Fmin, SpO2 \\> 92% without supplemental oxygen.\n5. Able to tolerate oral or enteral medications.\n6. Men and women of reproductive potential must agree to follow accepted birth control methods for the duration of the study. Female subject is either post-menopausal or surgically sterilized or willing to use an acceptable method of birth control (i.e., a hormonal contraceptive, intra-uterine device, diaphragm with spermicide, condom with spermicide, or abstinence) for the duration of the study. Male subject agrees to use an acceptable method for contraception for the duration of the study.\n7. Able to read and sign informed consent.\n\nExclusion Criteria:\n\n1. Anaplastic lymphoma kinase (ALK)+ or Dual specificity 22 (DUSP22)+ ALCL with low international prognostic index (IPI) score (\\\u003C2) in first complete remission.\n2. Progressive disease or any other systemic therapy post-SCT (radiation allowed)\n3. Disease progression to Ruxolitinib previously\n4. GvHD requiring systemic therapy.\n5. Active uncontrolled infections.\n6. Active thrombotic active microangiopathy requiring therapy.\n7. History of veno-occlusive disorder post-transplant\n8. Use of platelets antiaggregant or anticoagulants deemed to be unsafe to be held in case of thrombocytopenia.\n9. History of life-threatening bleeding defined as any bleeding that required invasive procedures or involving central nervous system.\n10. Pregnancy (positive Beta HCG test in a woman with childbearing potential defined as not postmenopausal for 12 months or no previous surgical sterilization) or currently breast-feeding. Pregnancy testing is not required for post-menopausal or surgically sterilized women.\n11. Uncontrolled Hepatitis B\u002FC, HIV, tuberculosis, mycobacterium, or fungal infection.\n12. Exposure to other investigational drugs within 4 weeks before enrollment.\n13. Grade ≥ 3 non-hematologic toxicity from SCT that has not resolved to grade ≤ 2.\n14. Myocardial infarction or stroke within 1 year of study entry.\n15. Any uncontrolled medical problem at the discretion of the investigator that would pose a risk to the patient.",{"count":233,"type":22},[84],"This phase II trial tests how well ruxolitinib as a maintenance medication works to prevent relapse and graft-versus-host disease (GVHD) for patients who have undergone stem cell transplantation for T-cell lymphoma. GVHD is a common problem that may occur after a blood stem cell transplant. The \"graft\" is the donor blood cells that patients get during the transplant. The \"host\" is the person receiving the cells. GVHD is when the donor graft attacks and damages some of the transplant recipient's tissues. Ruxolitinib is a type of drug called a Janus kinase (JAK) inhibitor which works by decreasing the immune response of cells in the body. It is also a cancer growth blocker that blocks the growth factors that trigger the cancer cells to divide and grow. Ruxolitinib works by blocking a gene, called JAK2, that is important in the production of cancer cells.",[339,29,340,341,342,343,344,345],"T-cell Lymphoma","Lymphoma, T-Cell","Peripheral T Cell Lymphoma","T-cell Prolymphocytic Leukemia","Cutaneous T Cell Lymphoma","Adult T-cell Leukemia\u002FLymphoma","Primary Cutaneous T-Cell Non-Hodgkin Lymphoma",[347,348,349,350],"stem cell transplant","graft versus host disease","lymphoma","leukemia","2026-04-10",{"date":353,"type":35},"2026-04-15",{"date":355,"type":35},"2026-02-12",{"date":357,"type":22},"2027-01-31",{"name":359,"class":42},"Jonathan Brammer",{"id":361,"slug":362,"hasResults":12,"nctId":363,"briefTitle":364,"officialTitle":365,"acronym":4,"eligibilityCriteria":366,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":367,"enrollmentInfo":368,"targetDuration":4,"studyType":23,"phases":370,"briefSummary":372,"conditions":373,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":374,"lastUpdatePostDateStruct":375,"startDateStruct":377,"completionDateStruct":379,"leadSponsor":381,"locationsCount":43},"100388414","a-feasibility-study-using-clinimacs-for-alphabeta-t-cell-depletion-in-stem-cell-transplant-100388414","NCT04337515","A Feasibility Study Using CLINIMACS® for Alpha\u002FBeta T-Cell Depletion in Stem Cell Transplant","A Feasibility Study of Using the CiniMacs® Device for Alpha\u002FBest T-Cell Depletion in Stem Cell Transplant Recipients","Inclusion Criteria:\n\n* Male or female 0-30 years of age at time of transplant admission\n* Documentation of a disease requiring HCT\n* A donor (mismatched related or unrelated) must be located who are healthy and willing, and whom are able to donate bone marrow (BM) or peripheral blood stem cells (PBSC). Matched related donors may be used for patients with Fanconi Anemia.\n* Written informed consent (and assent when applicable) obtained from subject or subject's legal representative and ability for subject to comply with the requirements of the study\n\nExclusion Criteria:\n\n* Pregnant, breastfeeding, or unwilling to practice birth control during participation in the study\n* Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data\n* Presence of a healthy and willing HLA-identical related donor (except when the patient has Fanconi Anemia).\n* Patient with an anticipated life expectancy of \\\u003C1 month\n* Patients with known hypersensitivity to murine (mouse) proteins or iron dextran","30 Years",{"count":369,"type":22},90,[371],"NA","Patients in need of an allogeneic hematopoietic cell transplant (HCT) are at risk of developing graft-versus-host-disease (GVHD). In certain clinical situations, the optimal approach to minimize the risk of GVHD is to perform ex vivo alpha-beta T-cell depletion of the donor cells. However, the CliniMACS® Device is FDA-approved only for a narrow indication. All other uses of ex vivo processed cells must be done under a feasibility study protocol.",[87,139],"2026-04-06",{"date":376,"type":35},"2026-04-13",{"date":378,"type":35},"2019-12-19",{"date":380,"type":22},"2035-01-01",{"name":382,"class":42},"Christopher Dvorak",{"id":384,"slug":385,"hasResults":12,"nctId":386,"briefTitle":387,"officialTitle":388,"acronym":4,"eligibilityCriteria":389,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":390,"enrollmentInfo":391,"targetDuration":4,"studyType":23,"phases":393,"briefSummary":395,"conditions":396,"keywords":398,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":402,"lastUpdatePostDateStruct":403,"startDateStruct":405,"completionDateStruct":407,"leadSponsor":409,"locationsCount":43},"100570270","phase-3-study-comparing-reduced-versus-standard-dose-post-transplantation-cyclophosphamide-in-combination-with-post-engraftment-anti-thymoglobin-as-graft-versus-host-disease-prophylaxis-in-alternative-donor-peripheral-stem-cell-transplantation-100570270","NCT06705062","Study Comparing Reduced Versus Standard Dose Post-transplantation Cyclophosphamide in Combination With Post-engraftment Anti-thymoglobin as Graft Versus Host Disease Prophylaxis in Alternative Donor Peripheral Stem Cell Transplantation","A Multi-center Randomized Clinical Study Comparing Reduced-dose (35mg\u002Fkg) Versus Standard Dose (50mg\u002Fkg) Post-transplantation Cyclophosphamide in Combination With Post-engraftment Anti-thymoglobin (ATG) and Tacrolimus and Post-engraftment Anti-thymoglobin as Graft Versus Host Disease (GVHD) Prophylaxis in Patients Undergo Alternative Donor Peripheral Hematopoietic Stem Cell Transplantation","Inclusion Criteria:\n\n1. patients undergo allo-HSCT with matched unrelated donor or haplo-identical donor;\n2. normal organ function (creatinine clearance ≥ 50ml\u002Fmin\u002F1.73m2 or creatinine ≤2mg\u002Fd(or 177μmol\u002FL); no hepatic abnormal (ALT or AST≤2.5xN; TBil≤1.5XN); Normal pulmonary function (FEV1、 FVC、DLCO≥80%); normal cardiac function (EFS ≥50%);\n3. ECOG: 0-2;\n4. Life expectation ≥3 months;\n5. Informed consent provided.\n\nExclusion Criteria:\n\n1. Pregnancies\n2. active hepatitis (HBV-DNA≥1×103 copies\u002Fml);\n3. active infection require anti-biotics;\n4. HIV infection","55 Years",{"count":392,"type":22},316,[394],"PHASE3","This is a multi-center randomized study to compare the reduced-dose of post-transplantation cyclophosphamide (PTCY) at 35mg.kg to standard dose at 50mg\u002Fkg combined with tacrolimus and post-engraftment low dose anti-thymoglobin (ATG) as graft versus host disease (GVHD) prophylaxis in patients undergoing allogeneic stem cell transplantation from alternative donor.",[397,29],"Allogeneic Hematopoietic Cell Transplant",[399,400,401,348],"post-transplantation cyclophosphamide","prophylaxis","reduced dose","2026-03-15",{"date":404,"type":35},"2026-03-17",{"date":406,"type":35},"2025-01-01",{"date":408,"type":22},"2028-07-01",{"name":410,"class":42},"Shanghai Jiao Tong University School of Medicine",{"id":412,"slug":4,"hasResults":12,"nctId":413,"briefTitle":414,"officialTitle":414,"acronym":4,"eligibilityCriteria":415,"healthyVolunteers":12,"sex":17,"minAge":416,"maxAge":4,"enrollmentInfo":417,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":419,"conditions":420,"keywords":4,"overallStatus":215,"whyStopped":4,"lastUpdateSubmitDate":421,"lastUpdatePostDateStruct":422,"startDateStruct":424,"completionDateStruct":426,"leadSponsor":428,"locationsCount":43},"100611047","NCT07235501","Kinetic Analysis of Immune Cells in Blood and Chronic Graft-Versus-Host Disease-Affected Tissues After Allogeneic Hematopoietic Cell Transplantation","Inclusion Criteria:\n\n* \\* BOTH COHORTS:\n\n  * Documented written informed consent of the participant and\u002For parent\u002Fguardian.\n\n    * Assent from pediatric participants will be documented per institutional policies and practice.\n  * Patients who have received allogeneic hematopoietic cell transplant (HCT) regardless of donor type, condition regimen, or GVHD prophylaxis.\n  * Age: ≥ 18 years or ≥ 7 years if 30 kg and above\n  * Willingness to:\n\n    * Provide blood sample(s), stool, saliva, and buccal mucosa,\n    * If applicable: Permit medical record\u002F clinical laboratory result review\n\n      * COHORT 1:\n  * Patients who have received allogeneic hematopoietic cell transplant (HCT) regardless of donor type, condition regimen, or GVHD prophylaxis.\n\n    * COHORT 2:\n  * Patients diagnosed with cGVHD at any time-point after allogeneic HCT regardless of donor type, condition regimen, or GVHD prophylaxis.\n\nExclusion Criteria:\n\n* \\* Women of childbearing potential: Pregnant\u002Fnursing\n\n  * Individuals with impaired decision-making capacity\n  * An employee who is under the direct\u002F indirect supervision of the PI\u002F a co-investigator\u002F the study manager\n  * A direct study team member","7 Years",{"count":418,"type":22},75,"This study evaluates the factors that contribute to chronic graft-versus-host disease, which is a complication that can occur after allogeneic hematopoietic cell transplantation.",[29,213,214],"2026-03-11",{"date":423,"type":35},"2026-03-13",{"date":425,"type":22},"2026-06-01",{"date":427,"type":22},"2028-04-11",{"name":41,"class":42},{"id":430,"slug":431,"hasResults":12,"nctId":432,"briefTitle":433,"officialTitle":434,"acronym":435,"eligibilityCriteria":436,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":437,"targetDuration":4,"studyType":23,"phases":439,"briefSummary":440,"conditions":441,"keywords":444,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":450,"lastUpdatePostDateStruct":451,"startDateStruct":453,"completionDateStruct":455,"leadSponsor":457,"locationsCount":459},"100586099","multidisciplinary-intervention-for-adults-with-chronic-graft-versus-host-disease-100586099","NCT06910969","Multidisciplinary Intervention for Adults With Chronic Graft-versus-host Disease","Multi-Site Randomized Controlled Trial of A Multidisciplinary Intervention for Adults With Chronic Graft Versus Host Disease","HORIZONS","Inclusion Criteria:\n\n* Adult patients (≥ 18 years) who have undergone allogeneic HCT\n* Have moderate to severe cGVHD based on patient-report\n* Have ability to participate in English or Spanish language group telehealth intervention.\n\nExclusion Criteria:\n\n* Patients with mild cGVHD based on their self-report.\n* Patients with a major untreated psychiatric or cognitive condition which the treating oncology clinicians believes interferes with the capacity to provide informed consent.\n* Patients with active relapsed disease requiring therapy.",{"count":438,"type":22},350,[371],"The goal of this study is to demonstrate the efficacy of a multidisciplinary group-based telehealth intervention (HORIZONS) compared to minimally enhanced usual care for improving self-management and quality of life for hematopoietic stem cell transplant (HSCT) survivors living with chronic graft-versus host disease, and to identify critical facilitators and barriers for HORIZONS implementation and adoption.",[442,443],"Bone Marrow Transplant Complications","Graft-versus-Host Disease",[445,446,447,448,449],"neoplasms","hematologic diseases","neoplasms by site","hematologic neoplasms","graft-versus-host disease","2026-03-01",{"date":452,"type":35},"2026-03-03",{"date":454,"type":35},"2025-08-13",{"date":456,"type":22},"2030-02-01",{"name":458,"class":42},"Massachusetts General Hospital",2,{"id":461,"slug":462,"hasResults":12,"nctId":463,"briefTitle":464,"officialTitle":465,"acronym":4,"eligibilityCriteria":466,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":467,"enrollmentInfo":468,"targetDuration":4,"studyType":23,"phases":470,"briefSummary":471,"conditions":472,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":473,"lastUpdatePostDateStruct":474,"startDateStruct":476,"completionDateStruct":478,"leadSponsor":480,"locationsCount":43},"100430565","phase-1-ptcy-plus-uhcgegf-for-graft-versus-host-disease-prophylaxis-100430565","NCT04886726","PTCY Plus uhCG\u002FEGF for Graft Versus Host Disease Prophylaxis","Post-transplant Cyclophosphamide and Urinary-derived Human Chorionic Gonadotropin and Epidermal Growth Factor (uhCG\u002FEGF) as Graft Versus Host Disease Prophylaxis for Mismatched Unrelated Donor Transplantation","Inclusion Criteria:\n\n1. Patients with hematologic malignancy who have the indication for Allogeneic SCT and have no MRD or MUD.\n2. Age 18-70 years old\n3. Performance score of at least 80% by Karnofsky\n4. Adequate kidney and liver function as demonstrated by:\n\n   1. Creatinine clearance should be \\>60 ml\u002Fmin\n   2. Total Bilirubin \\\u003C1.5, ALT\u002FAST\u002FAlk Phos \\\u003C 2.5 x normal. No evidence of chronic active hepatitis or cirrhosis.\n5. Negative Beta HCG test in a woman with childbearing potential, defined as not post-menopausal for 12 months or no previous surgical sterilization. Women of childbearing potential must be willing to use an effective contraceptive measure while on study.\n6. Patient or patient's legal representative, parent(s) or guardian able to sign informed consent.\n\nExclusion Criteria:\n\n1. Positive for HIV, HBsAg, HCV or other viral hepatitis or cirrhosis from any cause\n2. Active or prior CNS leukemia, unless in complete remission for at least 2 months.\n3. History of serious chronic mental disorder or drug-abuse accompanied by documented problems of compliance with therapeutic programs.\n4. Uncontrolled infection\n5. Donor specific antibodies\n6. Ejection fraction \\\u003C40% or history of heart failure or cardiovascular disease\n7. history thrombosis or current thrombosis, family history of thrombosis, severe obesity, or thrombophilia.\n8. Previous history hormone responsive cancer\n9. history of seizure\n10. history of migraine or severe headache\n11. history of asthma\n12. history of uterine fibroid","70 Years",{"count":469,"type":22},18,[25],"So this a Phase I study with primary objective to determine the feasibility and safety of combining post-transplant cyclophosphamide and urinary-derived human chorionic gonadotropin and epidermal growth factor (uhCG\u002FEGF) as graft versus host disease prophylaxis in stem cell transplant with MMUDs Secondary objectives are to determine the incidence acute and chronic GVHD, progression-free survival , and overall survival",[29],"2026-02-23",{"date":475,"type":35},"2026-02-24",{"date":477,"type":35},"2021-12-23",{"date":479,"type":22},"2028-11-30",{"name":481,"class":42},"Henry Ford Health System",{"id":483,"slug":484,"hasResults":12,"nctId":485,"briefTitle":486,"officialTitle":487,"acronym":488,"eligibilityCriteria":489,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":467,"enrollmentInfo":490,"targetDuration":4,"studyType":23,"phases":492,"briefSummary":493,"conditions":494,"keywords":495,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":499,"lastUpdatePostDateStruct":500,"startDateStruct":502,"completionDateStruct":504,"leadSponsor":506,"locationsCount":508},"100535518","phase-2-study-testing-two-conditioning-regimen-with-a-single-prophylaxis-of-gvhd-by-cyclophosphamide-and-methotrexate-post-transplant-in-patients-eligible-for-matched-donor-allograft-transplantation-100535518","NCT06252870","Study Testing Two Conditioning Regimen With a Single Prophylaxis of GVHD by Cyclophosphamide and Methotrexate Post-transplant in Patients Eligible for Matched-donor Allograft Transplantation","Randomized Phase 2 Study Testing Two Conditioning Regimen With a Single Prophylaxis of Graft-versus-host Disease by Cyclophosphamide and Methotrexate Post-transplant in Patients Eligible for Matched-donor Allograft Transplantation","CY-MET-RIC","Inclusion Criteria:\n\n* Age: ≥ 18 and ≤ 70 years old\n* Patient with hematologic malignancy\n* Indication for HSC allograft with attenuated conditioning\n* Pluripotent stem cell (PSC) engraftment\n* Availability of a 10\u002F10 familial or non-familial HLA compatible donor\n* Consent to the protocol\n* ECOG \\\u003C=2\n* Woman of childbearing age with negative pregnancy test and on highly effective contraception during treatment and for a period of 12 months after stopping MTX and CY\n* Man of childbearing age with highly effective contraception during treatment and for a period of 6 months after stopping MTX and CY and a period of 12 months after stopping MTX and CY if TBF conditioning regimen arm\n* Negative Hepatitis B, C, HIV serologies\n* Social security affiliation\n\nExclusion Criteria:\n\n* History of allograft\n* Patient eligible for myeloablative conditioning (MAC)\n* Bone marrow transplant\n* Other progressive cancerous disease, or antecedent of cancer in the last five years, with the exception of a carcinoma of the skin or a carcinoma in situ of the uterine cole treated and in remission.\n* Progressive psychiatric condition\n* Pregnant or breastfeeding woman,\n* Woman or man of childbearing age with lack of effective contraception\n* Serious and uncontrolled concomitant infection\n* Cardiac: systolic ejection fraction \\\u003C 50% by transthoracic ultrasound or by isotopic method (isotope gamma angiography), NYHA II, III or IV heart failure, active rhythmic, valvular or ischemic heart disease or anteriority\n* Respiratory with EFR: DLCOc \\\u003C40% of theoretical\n* Renal: creatinine clearance \\\u003C 50 ml\u002Fmin (assessment with MDRD method)\n* Urological: active urinary tract infection, history of acute urothelial toxicity due to cytotoxic chemotherapy or radiotherapy, known obstruction of urinary flow, pre-existing hemorrhagic cystitis\n* Hepatic: transaminases greater than 5 times normal or bilirubin greater than 2 times normal\n* Person protected by law (major under guardianship, curatorship or legal protection)\n* Vaccination against yellow fever in the last year\n* Known or suspected hypersensitivity to rabbit proteins as well as to the active substance and excipients of all investigational and ancillary drugs administered during the study,\n* Contraindication to any of the investigational or adjuvant drugs administered during the study\n* Patient not speaking French",{"count":491,"type":22},82,[84],"Graft-versus-host disease (GVHD) is a major complication of allogeneic hematopoietic stem cell transplantation (allo-CSH).\n\nRecently, in the context of semi-identical (=haploidentical) HLA donors, but also of compatible HLA donors, the use of cyclophosphamide (CY) administered in high doses at early post-transplant (PT) (=PTCY) (Days +3 and +4 or +5) has shown excellent control of acute and chronic GVH, even enabling the discontinuation of other immunosuppressive drugs administered after allo-CSH (ciclosporin, mycophenolate mofetyl (MMF) or Cellcept).\n\nThis step has already been taken in the context of allo-CSH with myeloablative conditioning (MAC), which is a minoritary conditioning in adults.\n\nHowever, in the context of allo-CSH with reduced-intensity conditioning (RIC), which predominates in adults, this strategy seems insufficient to prevent the risk of GVHD.\n\nThe idea of reducing the use of immunosuppressants in the context of RIC\u002FHLA-compatible transplants seems, however, still relevant, in order to reduce their adverse effects, improve patients' quality of life and enhance the reconstitution of the post-transplant immune system.",[29,88],[496,497,498],"Hematopoietic stem cell allograft (Allo-CSH)","Methotrexate (MTX)","Post-transplant cyclophosphamide (PTCY)","2026-01-23",{"date":501,"type":35},"2026-01-26",{"date":503,"type":35},"2024-07-18",{"date":505,"type":22},"2028-07-18",{"name":507,"class":42},"Nantes University Hospital",3,{"id":510,"slug":511,"hasResults":12,"nctId":512,"briefTitle":513,"officialTitle":514,"acronym":4,"eligibilityCriteria":515,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":52,"enrollmentInfo":516,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":518,"conditions":519,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":520,"lastUpdatePostDateStruct":521,"startDateStruct":523,"completionDateStruct":525,"leadSponsor":527,"locationsCount":43},"100413200","relationship-between-fodmaps-and-gvhd-100413200","NCT04660487","Relationship Between \"FODMAPs\" and \"GVHD\"","Relationship Between the Utilization and Degradation Rate of \"FODMAPs\" by Intestinal Flora and \"GVHD\"","Inclusion Criteria:\n\n1. Clinical diagnosis of \"AML\",\"ALL\",\"MDS\" or \"MM\" Disease;\n2. Must be treated with bone marrow transplantation;\n3. The transplanted bone marrow was successfully planted\n\nExclusion Criteria:\n\n1. Gastrointestinal diseases；\n2. Age\\>60; or Age\\\u003C10；\n3. Probiotics or prebiotics were taken before enrollment",{"count":517,"type":22},100,"With the stem cell transplanting increasing, patients which effected with \"GVHD\" were also increased. To evaluation the relationship between \"FODMAPs\" and \"GVHD\", Bone marrow transplant patients were recruited.",[29],"2025-12-24",{"date":522,"type":35},"2025-12-31",{"date":524,"type":35},"2020-12-01",{"date":526,"type":22},"2026-12-01",{"name":528,"class":42},"The First Affiliated Hospital of Soochow University",{"id":530,"slug":531,"hasResults":12,"nctId":532,"briefTitle":533,"officialTitle":534,"acronym":4,"eligibilityCriteria":535,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":467,"enrollmentInfo":536,"targetDuration":4,"studyType":23,"phases":538,"briefSummary":539,"conditions":540,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":541,"lastUpdatePostDateStruct":542,"startDateStruct":544,"completionDateStruct":546,"leadSponsor":548,"locationsCount":312},"100568510","phase-3-evaluation-of-rovadicitinib-compared-to-the-protocol-selected-by-researchers-in-third-line-and-subsequent-studies-of-moderate-to-severe-chronic-graft-versus-host-disease-100568510","NCT06682169","Evaluation of Rovadicitinib Compared to the Protocol Selected by Researchers in Third Line and Subsequent Studies of Moderate to Severe Chronic Graft-versus-host Disease","A Randomized, Open Label, Positive Controlled, Multicenter Phase III Clinical Trial Evaluating the Efficacy and Safety of the Selected Regimen of Rovadicitinib in Moderate to Severe Chronic Graft-versus-host Disease in Third Line and Beyond","Inclusion Criteria:\n\n* Age: 18 to 70 years old; Karnofsky (KPS) ≥ 60 points; Expected survival period exceeding 6 months;\n* Previously received allogeneic hematopoietic stem cell transplantation;\n* According to NIH standards, the clinical diagnosis is moderate to severe cGVHD；\n* Previously received systematic treatment for cGVHD with 2-5 lines;\n* Stable dosage of corticosteroids and other immunosuppressants received within 2 weeks prior to screening;\n* The main organ functions well;\n* Starting from Day 1 after enrollment in the control group of this study, participants must receive one of the drugs specified in the study protocol;\n* Female participants of childbearing age should agree to use contraceptive measures (such as intrauterine devices, birth control pills, or condoms) during the study period and for 6 months after the end of the study; Serum pregnancy test negative within 7 days prior to enrollment in the study, and must be a non lactating subject; Male participants should agree to use contraceptive measures during the study period and within 6 months after the end of the study period;\n* Subjects voluntarily joined this study, signed informed consent, and had good compliance.\n\nExclusion Criteria:\n\n* Has experienced or currently suffers from other malignant tumors within the past 3 years;\n* Known or suspected active aGVHD；\n* Individuals with interstitial pneumonia, non infectious pneumonia, uncontrolled active infections, or infections requiring systematic treatment within the first 7 days of randomization, except for those deemed suitable for inclusion by the researchers;\n* The occurrence and progression of other underlying diseases include post transplant lymphoid tissue proliferative diseases and recurrence of primary malignant hematological diseases;\n* Random failure of allogeneic hematopoietic stem cell transplantation within the first 6 months or having received 2 allogeneic hematopoietic stem cell transplants in the past;\n* Used JAK inhibitors, Bruton's tyrosine kinase (BTK) inhibitors, etc. within the first 2 weeks of randomization;\n* There are multiple factors that can affect oral medication, such as inability to swallow, intestinal obstruction, etc;\n* Individuals with a history of abuse of psychotropic drugs who are unable to quit or have mental disorders;\n* Subjects with any severe and\u002For uncontrolled illnesses;\n* Individuals who are allergic to research drugs or their components;\n* Participated in other clinical trials within the first 4 weeks of randomization;\n* According to the researcher's judgment, there are accompanying diseases that seriously endanger the safety of the subjects or affect the completion of the study, or subjects who are deemed unsuitable for inclusion due to other reasons.",{"count":537,"type":22},182,[394],"The aim of this study is to demonstrate that in subjects with moderate to severe chronic graft-versus-host disease in the third line and beyond, the use of rosuvastatin compared to the protocol chosen by the researchers can significantly improve the objective response rate of subjects at week 24.",[189],"2025-12-05",{"date":543,"type":35},"2025-12-08",{"date":545,"type":35},"2024-11-20",{"date":547,"type":22},"2030-12",{"name":549,"class":174},"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.",{"id":551,"slug":552,"hasResults":12,"nctId":553,"briefTitle":554,"officialTitle":555,"acronym":4,"eligibilityCriteria":556,"healthyVolunteers":12,"sex":17,"minAge":557,"maxAge":4,"enrollmentInfo":558,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":560,"conditions":561,"keywords":564,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":566,"lastUpdatePostDateStruct":567,"startDateStruct":569,"completionDateStruct":571,"leadSponsor":573,"locationsCount":575},"100505816","parametric-response-mapping-prm-for-the-detection-of-chronic-lung-injury-in-hematopoietic-cell-transplant-recipients-100505816","NCT05866302","Parametric Response Mapping (PRM) for the Detection of Chronic Lung Injury in Hematopoietic Cell Transplant Recipients","Parametric Response Mapping (PRM) for the Detection of Chronic Lung Injury in Hematopoietic Cell Transplant Recipients. A Multi-center, Observational Trial.","Inclusion Criteria:\n\n* For both Cohorts 1 and 2:\n* Age ≥ 36 months. There is no upper age limit.\n* Receipt of an allogeneic HCT. There are no exclusions to study entry based upon primary diagnosis, hematopoietic cell source, conditioning regimen, donor type, degree of donor-recipient HLA match, or current organ function.\n* All patients and\u002For their parents or legal guardians must sign a written informed consent. Assent, when appropriate, will be obtained according to institutional guidelines.\n* Cohort 1 (Chronic Graft Versus Host Disease): Diagnosis of chronic GVHD in at least 1 organ system within the prior 3 months. NIH Consensus Criteria for chronic GVHD are required to establish the diagnosis. (https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F25529383\u002F)\n* Cohort 2 (Chronic Lung Disease, CLD) Diagnosis of CLD within the prior 100 days, including either Bronchiolitis Obliterans Syndrome (BOS) or Restrictive lung disease (RLD), with each defined as follows: Bronchiolitis Obliterans Syndrome (BOS): (NIH Consensus Criteria)31 a.FEV1 \\\u003C 75% predicted, with a decline in absolute FEV1 \\> 10% compared to pretransplant baseline or within the prior 2 years, b.FEV1\u002FVC or FEV1\u002FFVC \\\u003C 0.7 , c. Absence of an alternative diagnosis, including COPD exacerbation, asthma, and active respiratory tract infection, as determined by appropriate clinical investigations that may include chest imaging, microbiologic cultures, and\u002For bronchoscopy, d. One of two supportive features of BOS: i. Evidence of air trapping by PFTs: RV\\>120%, or elevated RV\u002FTLC (\\>20% of predicted), ii. High resolution chest CT with inspiratory and expiratory cuts that show findings that are consistent with small airways disease including (but not exclusive of) air trapping, bronchial wall thickening, or bronchiectasis. Restrictive Lung Disease (RLD): a. ≥ 20% decline in FEV1 from baseline, coupled with ≥ 10% decline in total lung capacity (TLC) from baseline. If measurements of TLC are not available, then a ≥ 20% decline in FVC from baseline may be substituted for RLD.32, b.Radiographic opacities or infiltrates on chest radiograph or CT. Such changes may include, but are not limited to the presence of ground glass opacities, reticular changes, septal thickening, fibrotic changes or areas of consolidation.\n* Patients unable to perform PFT. For cohort 1, patient's too young (or physically unable) to perform PFT's remain eligible provided they meet all other eligibility criteria. For cohort 2, children too young (or physically unable) to perform PFT's are eligible provided they exhibit both clinical and radiographic features (on CT) consistent with CLD. Clinical features would include dyspnea, cough, and\u002For SpO2 \\\u003C 93% on room air. Radiographic features may include, but are not limited to the presence of air trapping, bronchial wall thickening, or bronchiectasis.\n\nExclusion Criteria:\n\n* Relapse of a patient's primary malignancy post-HCT, or the development of any secondary \"hematologic\" malignancy post-HCT.\n* The presence of an active, uncontrolled infection.\n* Patients who would require intubation solely for the purposes of obtaining a CT scan for PRM imaging. (In contrast, if a clinical CT is being performed as routine medical care to evaluate a patient's lung function, the patient is eligible and PRM imaging may be performed from that CT.)","36 Months",{"count":559,"type":22},375,"The study will have two separate patient cohorts: Cohort 1 will include patients with newly diagnosed chronic graft versus host disease (GVHD), whereas cohort 2 will include patients with newly diagnosed chronic lung disease (CLD). For cohort 1, the primary objective will be to characterize PRM metrics at the onset of chronic GVHD and determine if a PRM signature is present that will predict 1-year CLD free survival. For cohort 2, the primary objective will focus on characterizing PRM at the onset of CLD and determine if PRM can predict the trajectory in lung function decline in affected patients.",[562,563,29],"Chronic Lung Disease","Hematopoietic Cell Transplantation",[565],"Parametric response mapping","2025-10-16",{"date":568,"type":35},"2025-10-20",{"date":570,"type":35},"2023-05-30",{"date":572,"type":22},"2028-05",{"name":574,"class":42},"University of Michigan Rogel Cancer Center",6,{"id":577,"slug":578,"hasResults":12,"nctId":579,"briefTitle":580,"officialTitle":581,"acronym":4,"eligibilityCriteria":582,"healthyVolunteers":12,"sex":17,"minAge":583,"maxAge":183,"enrollmentInfo":584,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":586,"conditions":587,"keywords":588,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":595,"lastUpdatePostDateStruct":596,"startDateStruct":598,"completionDateStruct":600,"leadSponsor":602,"locationsCount":603},"100487027","a-pms-of-jakavi-in-patients-with-steroid-refractory-graft-versus-host-disease-sr-gvhd-in-korea-100487027","NCT05621733","A PMS of Jakavi® in Patients With Steroid-Refractory Graft-versus-Host Disease (SR-GvHD) in Korea","A Post Marketing Surveillance of Jakavi® (Ruxolitinib) in Patients With Steroid-Refractory Graft-versus-Host Disease (SR-GvHD) in Korea","Inclusion Criteria:\n\n1. Patients who diagnosed with GvHD and currently receiving or going to receive Jakavi® treatment according to locally approved label\n2. Patients who are willing to provide written informed consent prior to study enrollment\n\nExclusion Criteria:\n\n1. Patients under 12 years old\n2. Patients with contraindication according to locally approved label of Jakavi®\n3. Patients who receive or are going to receive any investigational medicine during the observation period.","12 Years",{"count":585,"type":22},127,"This study is a prospective, open-label, multi-center, non-comparative, observational study to assess safety and effectiveness of Jakavi® (ruxolitinib) in the real-world clinical setting in Korean Graft-versus-Host disease (GvHD) patients",[443],[589,590,591,592,593,594],"Graft-versus-Host disease","GvHD","NIS","Korea","ruxolitinib","Jakavi","2025-08-06",{"date":597,"type":35},"2025-08-11",{"date":599,"type":35},"2023-04-07",{"date":601,"type":22},"2026-05-09",{"name":173,"class":174},11,{"id":605,"slug":606,"hasResults":12,"nctId":607,"briefTitle":608,"officialTitle":609,"acronym":610,"eligibilityCriteria":611,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":612,"enrollmentInfo":613,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":615,"conditions":616,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":628,"lastUpdatePostDateStruct":629,"startDateStruct":631,"completionDateStruct":633,"leadSponsor":635,"locationsCount":43},"100540758","systematical-trained-learning-algorithms-for-oral-carcinogenesis-interpretation-by-optical-coherence-tomography-100540758","NCT06321003","SYsteMatical Trained learnIng aLgorithms for Oral carcInogenesiS Interpretation by Optical Coherence Tomography","Single-blind Clinical Trial Assessing the Validity of Optical Coherence Tomography (OCT) in Diagnosing Potentially Malignant Oral Lesions and Oral Cancer","SYMILIS OCT","Inclusion Criteria:\n\n1. Adult patients with clinical suspicion of potentially malignant oral disorders (OPMDs) and oral squamous cell carcinoma (OSCC).\n2. Patients able to provide informed consent for participation in the study.\n3. Availability of complete clinical data and medical records.\n\nExclusion Criteria:\n\n1. Patients with a previous diagnosis of OSCC\u002FOPMDs and\u002For who have already undergone treatment.\n2. Patients with contraindications to the OCT examination for nonpermissive oral localization using the probe.\n3. Pregnant or breastfeeding women.\n4. Patients with disabilities, reluctance or difficulties of understanding to follow the procedures of the study and who have not provided a consent.","99 Years",{"count":614,"type":22},200,"This clinical trial aims to assess the efficacy of Optical Coherence Tomography (OCT) in the early diagnosis of oral cancer. It focuses on Oral Potentially Malignant Disorders (OPMDs) as precursors to Oral Squamous Cell Carcinoma (OSCC). Despite the availability of oral screening, diagnostic delays persist, underscoring the importance of exploring non-invasive methodologies. The OCT technology provides cross-sectional analysis of biological tissues, enabling a detailed evaluation of ultrastructural oral mucosal features.\n\nThe trial aims to compare OCT preliminary evaluation with traditional histology, considered the gold standard in oral lesion diagnosing. It seeks to create a database of pathological OCT data, facilitating the non invasive identification of carcinogenic processes. The goal is to develop a diagnostic algorithm based on OCT, enhancing its ability to detect characteristic patterns such as the keratinized layer, squamous epithelium, basement membrane, and lamina propria in oral tissues affected by OPMDs and OSCC.\n\nFurthermore, the trial aims to implement Artificial Intelligence (AI) in OCT image analysis. The use of machine learning algorithms could contribute to a faster and more accurate assessment of images, aiding in early diagnosis. The trial aims to standardize the comparison between in vivo OCT images and histological analysis, adopting a site-specific approach in biopsies to improve correspondence between data collected by both methods.\n\nIn summary, the trial not only evaluates OCT as a diagnostic tool but also aims to integrate AI to develop a standardized approach that enhances the accuracy of oral cancer diagnosis, providing a significant contribution to clinical practice.",[617,618,619,620,621,622,139,623,624,625,626,627],"Oral Squamous Cell Carcinoma","Oral Potentially Malignant Disorder","Oral Leukoplakia","Proliferative Verrucous Leukoplakia","Oral Lichen Planus","Oral Lichenoid Lesion","Oral Erythroplakia","Actinic Keratoses","Actinic Cheilitis","Oral Cancer","Oral Disease","2025-05-19",{"date":630,"type":35},"2025-05-23",{"date":632,"type":35},"2024-03-13",{"date":634,"type":22},"2028-04-01",{"name":636,"class":42},"University of Palermo",{"id":638,"slug":639,"hasResults":12,"nctId":640,"briefTitle":641,"officialTitle":642,"acronym":4,"eligibilityCriteria":643,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":644,"targetDuration":4,"studyType":23,"phases":646,"briefSummary":647,"conditions":648,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":675,"lastUpdatePostDateStruct":676,"startDateStruct":678,"completionDateStruct":680,"leadSponsor":682,"locationsCount":43},"100363607","safety-and-efficacy-of-fecal-microbiota-transplantation-100363607","NCT04014413","Safety and Efficacy of Fecal Microbiota Transplantation","Safety and Efficacy of Fecal Microbiota Transplantation: A Pilot Study","Inclusion Criteria:\n\nConfirmed diagnosis of any of the following diseases:\n\n* Crohn's disease\n* Ulcerative colitis\n* Celiac disease\n* Irritable bowel syndrome\n* Functional dyspepsia\n* Constipation\n* Antibiotic-associated diarrhea or any antibiotic- associated complications\u002Fsymptoms\n* Metabolic syndrome such as diabetes mellitus and obesity\n* Multidrug-resistant infection\n* Hepatic encephalopathy\n* Multiple sclerosis\n* Pseudo-obstruction\n* Carbapenem-resistant Enterobacteriaceae (CRE) or Vancomycin-resistant Enterococci (VRE) infection\n* Multiple organ dysfunction\n* Dysbiotic bowel syndrome\n* MRSA enteritis\n* Pseudomembranous enteritis\n* Alopecia, autism\n* Graft-versus-host disease\n* Idiopathic thrombocytopenic purpura (ITP)\n* Atopy or allergy\n* Liver disease such as Nonalcoholic fatty liver disease (NAFLD) and Nonalcoholic steatohepatitis (NASH)\n* Alcohol dependence\n* Psoriatic arthropathy that has suboptimal control of disease despite standard treatment.\n\nExclusion Criteria:\n\n* Known contraindication to all FMT infusion method such as nasoduodenal tube insertion, oesophago-gastro-duodenoscopy (OGD), enteroscopy, colonoscopy and enema\n* Any conditions that may render the efficacy of FMT or at the discretion of the investigators\n* Current pregnancy",{"count":645,"type":22},450,[371],"The gut microbiota is critical to health and functions with a level of complexity comparable to that of an organ system. Dysbiosis, or alterations of this gut microbiota ecology, have been implicated in a number of disease states. Fecal microbiota transplantation (FMT), defined as infusion of feces from healthy donors to affected subjects, is a method to restore a balanced gut microbiota and has attracted great interest in recent years due to its efficacy and ease of use. FMT is now recommended as the most effective therapy for CDI not responding to standard therapies.\n\nRecent studies have suggested that dysbiosis is associated with a variety of disorders, and that FMT could be a useful treatment. Randomized controlled trial has been conducted in a number of disorders and shown positive results, including alcoholic hepatitis, Crohn's disease (CD), ulcerative colitis (UC), pouchitis, irritable bowel syndrome (IBS), hepatic encephalopathy and metabolic syndrome. Case series\u002Freports and pilot studies has shown positive results in other disorders including Celiac disease, functional dyspepsia, constipation, metabolic syndrome such as diabetes mellitus, multidrug-resistant, hepatic encephalopathy, multiple sclerosis, pseudo-obstruction, carbapenem-resistant Enterobacteriaceae (CRE) or Vancomycin-resistant Enterococci (VRE) infection, radiation-induced toxicity, multiple organ dysfunction, dysbiotic bowel syndrome, MRSA enteritis, Pseudomembranous enteritis, idiopathic thrombocytopenic purpura (ITP), and atopy.\n\nDespite FMT appears to be relatively safe and efficacious in treating a wide range of disease, its safety and efficacy in a usual clinical setting is unknown. More data is required to confirm safety and efficacy of FMT. Therefore, the investigators aim to conduct a pilot study to investigate the efficacy and safety of FMT in a variety of dysbiosis-associated disorder.",[649,650,651,652,653,654,655,656,657,658,659,660,661,662,663,664,665,666,667,668,669,189,670,671,672,673,674],"Crohn Disease","Ulcerative Colitis","Celiac Disease","Irritable Bowel Syndrome","Functional Dysphonia","Constipation","Clostridium Difficile Infection","Diabetes Mellitus","Obesity","Multidrug -Resistant Infection","Hepatic Encephalopathy","Multiple Sclerosis","Pseudo-Obstruction","Carbapenem-Resistant Enterobacteriaceae Infection","Vancomycin Resistant Enterococci Infection","Multiple Organ Dysfunction Syndrome","Dysbiotic Bowel Syndrome","MRSA Enteritis","Pseudomembranous Enterocolitis","Alopecia","Autism","Idiopathic Thrombocytopenic Purpura","Atopy or Allergy","Liver Disease","Alcohol Dependence","Psoriatic Arthropathy","2024-08-21",{"date":677,"type":35},"2024-08-22",{"date":679,"type":35},"2019-07-15",{"date":681,"type":22},"2030-10-31",{"name":683,"class":42},"Chinese University of Hong Kong"]